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Joint inJUry anD osteoarthritis
Joints are important structures in the body, as they are anatomical locations for the union 
between two or more bones. The cartilage tissue that lines the long end of the bones 
provide sliding areas and consists of chondrocytes embedded within an extracellular 
matrix that contains distinct macromolecules such as proteoglycans and collagens. In 
contrast to various other tissues, cartilage has a very limited regeneration capacity due 
to the lack of vascularization of the tissue1. Synovial joints are enclosed by a synovial 
membrane, also known as the synovium, which produces synovial fluid that acts as 
lubricant to facilitate bone movement. Inflammation of the synovium is a major feature 
of osteoarthritis (OA) and its progression2-4. The synovium is comprised of connective 
tissue in which synoviocytes/fibroblasts and low percentages of T-cells, B-cell, and mast 
cells reside. Another essential cell type in the synovium, is the macrophage5,6. In the 
knee joint, the menisci and crucial ligaments are also important structures in addition 
to the cartilage. Studies have shown that patients who have sustained injury to the 
anterior cruciate ligament or menisci have an increased risk of developing OA7,8. OA is 
a degenerative joint disease that affects a large proportion of the population. Classically, 
it has been considered as a ‘wear-and-tear’ disorder resulting in the erosion of articular 
cartilage and subsequently exposure of the bone, though it is now known that many 
other processes such as inflammation are hallmarks of OA (Figure 1.1). Worldwide, 
4.8% of women and 2.8% of men suffer from OA9 and in the Netherlands alone, the 
prevalence of knee OA in people over 55 years of age is 30.5% in women and 15.6% 
in men10. Radiological OA appears even in 80% of the people over 70 years old11. As a 
result, the global economic burden exceeds 975 million euro per year for surgical costs 
and pain suppressing drugs and indirect costs are estimated to be over 3 billion euro12. 
In the last twenty-five years, it has become evident that OA should be identified as a 
degenerative disease that affects the whole joint and its surrounding tissues and also 
includes an inflammatory component13. In many cases, the disease leads to extensive 
pain and loss of function14,15. Due to ageing of the population, it is expected that in the 
upcoming 20 years the number of OA patients will have increased with 52%16.
Current clinical treatments for OA are primarily aimed to reduce and control 
symptoms. Physical therapy is a conservative treatment to strengthen the muscles 
around the joint; however, success is not always achieved and it is not considered 
a long-term solution. Pain can bevw temporarily treated with pharmaceuticals such 
as paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs). Intra-articular 
injections with corticosteroids can also relieve pain by reducing synovitis, though an 
important unwanted side-effect is chondrotoxicity17. Disease-modifying osteoarthritis 
drugs (DMOADs) are a group of mainly experimental, biological agents that are 
used with the intention to modify the course of the disease. Such agents include, but 
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are not limited to: matrix-metalloproteinases (MMPs) inhibitors, cytokine blockers, 
bisphosphonates, calcitonin, inducible nitric oxide synthase (iNOS) inhibitors18,19, 
and more recently, Wnt pathway inhibitors20. Another approach is not to inhibit pro-
inflammatory factors, but enhancing anti-inflammatory factors. A promising study 
that touches upon this aspect is a clinical trial where patients received intra-articular 
administration of recombinant interleukin (IL)-1RA after sustaining severe knee injury21. 
The IL-1RA therapy resulted in reduced knee pain and improved knee function, though 
the long-term effect on OA development was not assessed. This was further investigated 
in a small animal study22 using the closed articular fracture model for OA in C57BL/6 
mice. Intra-articular injection of IL-1RA resulted in less cartilage degeneration as 
evaluated by the histological Mankin score. Injection of IL1-RA also resulted in less 
synovitis than when the joints were injected with saline or a tumor necrosis factor alpha 
Healthy OA
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figure 1.1: the contrast between the healthy and osteoarthritic knee joint.
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(TNFα) inhibitor. Another study showed that IL-1RA knockout mice had worsened 
progression after induction of collagen-induced arthritis (CIA)23. If conservative 
treatments fail to alleviate pain, total replacement of the joint could be a last resort. 
Young patients who develop post-traumatic OA, for instance due to sports injuries, are 
less likely to be eligible for joint replacement surgeries. Although a prosthetic joint is 
an excellent solution to relieve pain and solve instability problems, prosthetics have a 
relatively short life span. On average, knee and hip prosthetics last approximately 15 
to 20 years before the need of replacement. Therefore, it is undesirable to subject these 
young patients to a total joint replacement surgery.
MonoCytes anD MaCroPhages
Macrophages in immunity and disease
Macrophages are immune cells that are virtually present in all tissues of the body. 
They can derive from blood monocytes and may polarize into activated macrophages 
when receiving cues from their microenvironment24, a concept that will be discussed 
in the next paragraph. Depending on the polarization state, macrophages express a 
repertoire of surface markers and produce a profile of cytokines that in turn contribute 
to the degree of inflammation of the tissue. Together with dendritic cells, macrophages 
aid to the innate immune response by producing cytokines that promote clearance 
of pathogens. By producing chemokines, macrophages contribute in some cases to 
the regulation of extravasation of additional leukocytes from the blood that augment 
the repression of the infection while an adaptive immune response is developing24. 
Unfortunately, the homeostatic function of macrophages can become compromised 
leading to their implication in many diseases25. For instance, Kupffer cells, which are 
the macrophages found on the luminal surface of hepatic sinusoids, and pulmonary 
macrophages are both macrophage types that are associated with tissue fibrosis. In the 
vasculature, circulating monocytes that are recruited to a lesion site contribute to the 
formation of atherosclerotic plaques. Macrophages are also implicated in obesity26 and 
inflammatory diseases such as inflammatory bowel disease, asthma, and rheumatoid 
arthritis27-33. The involvement of macrophages in numerous disorders demonstrates that 
it is an interesting cell type that could be deployed as a therapeutic option for the 
treatment of inflammatory degenerative joint diseases.
Macrophage polarization: fifty shades of grey?
Macrophage polarization is the concept in which monocytes are activated into 
macrophages and obtain a certain phenotype and function34. The M1/M2 nomenclature, 
proposed in 2000 by Mills et al.35, describes the phenotype of macrophages that can be 
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generated in vitro. This nomenclature was mainly based on the Th1 and Th2 classification 
of T-lymphocytes that was proposed earlier by Mosmann et al. in 198636. The M1/M2 
classification37-41 represents the very extremes of the macrophage phenotype spectrum: 
pro-inflammatory M1 or classically activated macrophages develop in vitro when 
monocytes are stimulated with granulocyte-macrophage colony-stimulating factor (GM-
CSF), interferon-γ (IFNγ), lipopolysaccharide (LPS), TNFα, or a combination of these 
factors. These pro-inflammatory macrophages have an increased microbicidal activity 
and express and secrete considerable amounts of pro-inflammatory factors, such as 
TNFα, IL-1β, IL-6, and chemokine (C-X-C motif) ligand (CXCL)1042. Anti-inflammatory 
M2 or alternatively activated macrophages can be further divided into the subtypes 
M2a, M2b and M2c. M2a-like macrophages can develop when monocytes are exposed 
to IL-4 and/or IL-13. These macrophages express and secrete for instance IL-10, 
IL-1RA, cluster of differentiation (CD)206, and C-C motif ligand (CCL)1843 and have an 
additional role in wound healing, tissue repair, and tissue remodeling40,44. The M2b-like 
subtype develops when exposed to immune complexes and LPS and have an immune 
regulatory function. This group is challenging to characterize because they produce 
both pro-inflammatory and anti-inflammatory cytokines, for instance low levels of 
IL-12 and high levels of IL-1039,40. The M2c-like subtype develops when monocytes are 
stimulated with IL-10 and glucocorticoids, and these macrophages express and secrete 
for instance IL-10, CD16342,45,46, and Transforming growth factor beta (TGF-β). They 
are characterized by their ability to down regulate the production of pro-inflammatory 
cytokines37,46 (Figure 1.2). The extremes of the macrophage spectrum of phenotypes can 
be acquired in vitro. Since the behavior of polarized macrophages can vary depending 
on the polarization method, Murray et al.47 advocated to specifically describe the 
activation state of macrophages by their stimuli. For example, pro-inflammatory 
M1 macrophages that have been polarized in vitro by IFNγ and TNFα should be 
described as M(IFNγ+TNFα), a terminology that will be applied throughout this thesis. 
Defining macrophage phenotypes remains a challenging task as the plasticity of the 
cells cause a spectrum of phenotypes that is currently only partially explored. The 
plasticity of macrophages can also be seen as an opportunity. Modulating, switching 
or reprogramming of the phenotype of a macrophage population in either direction to 
influence inflammation, is nowadays of high interest in multiple research areas, also in 
the field of OA research.
Macrophages in osteoarthritis
Besides their importance during innate and adaptive immunity, macrophages are 
pivotal in joint homeostasis and inflammation4. Early indications that they can affect 
joint tissue were seen in in vitro studies where it was reported that bone-marrow 
derived macrophages48 and peritoneal macrophages49 can secrete enzymes that 
13
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exacerbate degeneration of cartilage tissue. In respect to OA pathophysiology, 
increased percentage of macrophages in the synovium are observed6 and synovial 
macrophages were shown to be pivotal in the development of the disease50. This was 
demonstrated by in vivo studies where depletion of synovial macrophages diminished 
the formation of osteophyte51 and reduced cartilage destruction52 in OA mouse models. 
Recently, the association between macrophages and obesity-related osteoarthritis has 
also been reported53,54. It was shown that induced obesity in rats resulted in infiltration 
of pro-inflammatory macrophages in the synovium and contributed to OA processes50. 
Another study reported that temporary systemic depletion of macrophages, did not 
protect obese mice from actually developing OA. Additionally, the depletion caused 
enhanced inflammation54. In respect to joint tissue regeneration, it was shown that 
chondrogenesis is negatively affected when chondrogenically-stimulated mesenchymal 
stem cell (MSCs) pellets were cultured with the conditioned medium of human OA 
synovium5, infrapatellar fat pad55, and macrophages isolated from both tissues. These 
reports combined demonstrate that macrophages are important players during joint 
tissue degeneration and OA onset and progression. Therefore, in-depth research 
regarding the involvement of macrophages in OA has become of increasing interest in 
the last decade, mainly to understand the underlying pathophysiological mechanisms 
that could open up therapeutic possibilities.
Blood
Tissue
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Pro-infl ammatory
macrophage
Anti-infl ammatory
macrophage
Tissue repair
macrophage
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figure 1.2: spectrum of macrophage phenotypes. A spectrum of macrophage phenotypes can 
develop after monocytes receive cues from their environment.
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bioMateriaLs in regenerative MeDiCine
Biomaterials are materials of synthetic or natural origin that are used in contact 
with a biological environment56. These materials are frequently applied in the field 
of regenerative medicine to either support or replace damaged tissue in the body. 
For example, scaffolds or prosthetics used for joint reconstruction approaches or 
meshes that are applied during surgical procedures. Sutures are indispensable in 
modern medicine and though one may find it less obvious, they can be considered 
as biomaterials. An important aspect that all biomaterials have in common is the 
fact that upon implantation, the immune system of the host will interact with the 
material and will induce an immune reaction involving macrophages. Following the 
initiation by blood-martial contact, an acute inflammatory phase will begin during 
which monocytes and neutrophils are recruited and extravasate into the tissue. After 
the monocytes encounter the surface of the biomaterial, they will become activated 
and polarize into macrophages. Depending on their phenotype they may contribute 
to chronic inflammation, granulated tissue development, and a foreign body reaction 
will occur that is often followed by fibrosis (Figure 1.3)57. The cascade of the so-called 
foreign-body-reaction of the host upon biomaterial implantation, may determine the 
long-term integration of the material with the tissue. When this cascade is compromised, 
adverse effects may arise such as material-induced inflammation, excessive fibrosis, 
excessive coagulation, and infection58. Influencing macrophage polarization during this 
stage can be an approach to improve biomaterial integration for regenerative purposes.
aiM anD thesis oUtLine
Macrophages are plastic cells and depending on their phenotype can contribute to 
the inflammatory state of tissues. The main objective of this thesis is to explore the 
involvement of macrophages, in particular the role of their phenotypes, during 
processes of joint degeneration. The answers of the following questions contribute to 
the main objective:
• How are macrophages of different phenotypes involved in inflammatory tissue 
degeneration and degenerative joint disease?
• How can modulation of macrophage phenotypes be applied to control either 
inflammation or their response to biomaterials?
Synovial inflammation, and specifically increased number of macrophages, are 
observed during OA2. As macrophages can derive from monocytes, understanding 
mechanisms that are responsible for monocyte migration into tissue may be an approach 
15
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to develop new strategies to dampen tissue inflammation. Chemokines at the local 
site of inflammation facilitate and can regulate monocyte migration into the tissue. 
Therefore, we first investigate in chapter 2 the expressions of chemokines that are related 
to monocyte migration in synovial tissues of OA patients. We also assess associations 
between the chemokine expression profiles and the macrophage phenotypes present in 
the synovium and correlate these with the degenerative state of the articular cartilage. 
This knowledge may contribute to the development of management strategies focusing 
on monocyte/macrophage recruitment to control the progression of OA.
Macrophages of different phenotypes each have a signature comprised of a protein 
secretion profile, gene expression profile, and function. The effects of the secreted 
products of different phenotypes of macrophages on cartilage is unclear. Hence, we 
figure 1.3: Macrophage activation by a biomaterial. Monocytes are recruited to the implantation 
site and become activated macrophages.
Chapter 1
16
evaluated in chapter 3 the in vitro effects of three phenotypes on human articular 
cartilage explants by using conditioned medium of polarized macrophages.
In order to be able to know how to manage the phenotypes of macrophages, 
it should be determined which phenotypes are in fact involved and present during 
a certain stage of the disease. Therefore, in chapter 4 we determine profiles of the 
presence of three different macrophage phenotypes during the course of OA in two 
mouse models. Furthermore, associations between the presence of these macrophage 
phenotypes and different features of OA are assessed. Determining the macrophage 
phenotype profiles over time and investigating how different macrophage phenotypes 
affect joint tissues, provides an indication on the optimal time to intervene and which 
phenotypes to target.
Managing the inflammatory state of a tissue as a therapeutic approach can be 
accomplished by specific modulation of a macrophage population. The possibility to 
modulate the macrophage phenotype in synovial tissue in situ and how this concept 
may guide synovial inflammation, is explored in chapter 5. For this study, we evaluate 
the modulatory capacity of common used medications on synovial tissue and primary 
polarized macrophages.
As biomaterials are frequently used in reconstructive joint surgeries with the goal to 
prevent OA progression and are also used as in other fields of regenerative medicine, 
we explore in chapter 6 the polarization behavior of monocytes into macrophages in 
an in vitro culture model. Since obesity is a major risk factor for OA development, the 
association between specific subsets of monocytes and their inflammatory response 
is also assessed. The behavior of macrophages after activation by a biomaterial is 
determined by the type of material. In chapter 7, we evaluate in vitro the ability to 
modulate the acquired phenotype of macrophages with pharmaceuticals after they 
have been activated by biomaterials. The materials represent classes of frequently used 
materials in regenerative medicine.
Finally, chapter 8 provides a summary and general overview based on the presented 
work in this thesis, and aims to combine the knowledge of the studies to discuss the 
contribution of macrophage phenotypes during degenerative joint disease. It also 
provides potential directions on the use of monocyte and macrophage phenotype 
modulation as a tool to inhibit tissue degeneration.

3Cartilage inflammation and degeneration is enhanced by pro-inflammatory (M1) macrophages 
in vitro, but not inhibited directly by 
anti-inflammatory (M2) macrophages
Osteoarthritis Cartilage. 2016;24(12):2162-70
Lizette Utomo
Yvonne M. Bastiaansen-Jenniskens
Jan A.N. Verhaar
Gerjo J.V.M. van Osch
Chapter 3
34
abstraCt
Objective: Macrophages play a crucial role in the progression of osteoarthritis (OA). 
Their phenotype may range from pro-inflammatory to anti-inflammatory. The aim of 
this study was to evaluate the direct effects of macrophage subtypes on cartilage by 
culturing macrophage conditioned medium (MCM) on human articular cartilage.
Design: Human OA cartilage explants were cultured with MCM of pro-inflammatory 
M(IFNγ+TNFα), or anti-inflammatory M(IL-4) or M(IL-10) human monocyte-derived 
macrophages. To assess effects of anti-inflammatory macrophages, the cartilage 
was cultured with a combination of MCM phenotypes as well as pre-stimulated 
with IFNγ+TNFα cartilage before culture with MCM. The reactions of the explants 
were assessed by gene expression, nitric oxide (NO) production and release of 
glycosaminoglycans (GAGs).
Results: M(IFNγ+TNFα) MCM affected OA cartilage by upregulation of IL1B 
(Interleukin 1β), IL6, MMP13 (Matrix Metalloproteinase-13) and ADAMTS5 (A 
Disintegrin And Metalloproteinase with Thrombospondin Motifs-5), while inhibiting 
ACAN (aggrecan) and COL2A1 (collagen type II). M(IL-10) upregulated IL1B and 
Suppressor of cytokine signaling 1 (SOCS1). NO production and GAG release by the 
cartilage was increased when cultured with M(IFNγ+TNFα) MCM. M(IL-4) and M(IL-
10) did not inhibit the effects of M(IFNγ+TNFα) MCM of neither phenotype affected 
IFNγ+TNFα pre-stimulated cartilage, in which an inflammatory gene response was 
deliberately induced.
Conclusion: M(IFNγ+TNFα) macrophages have a prominent direct effect on OA 
cartilage, while M(IL-4) and M(IL-10) do not inhibit the effects of M(IFNγ+TNFα), or 
IFNγ+TNFα induced inflammation of the cartilage. Therapies aiming at inhibiting 
cartilage degeneration may take this into account by directing suppression of 
pro-inflammatory macrophages or stimulation of anti-inflammatory macrophages.
35
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introDUCtion
Knee osteoarthritis (OA) is a degenerative joint disease characterized by erosion of 
cartilage coupled with inflammation of the joint, eventually leading to pain and loss of 
function. If conservative treatment fails, total joint replacement may be the only option 
left open. This indicates that new insights into possibilities for delaying OA progression 
are necessary. Macrophages, together with fibroblasts, are present in the synovial lining 
of joints. They are involved in synovial inflammation, and have been shown to play a 
prominent role in the progression of OA51. Macrophages can become activated and may 
acquire a phenotype, ranging from pro-inflammatory (M1) to anti-inflammatory (M2)47. 
In vitro, pro-inflammatory macrophages develop when monocytes are subjected to 
interferon-γ (IFN-γ) and lipopolysaccharide (LPS) or tumor necrosis factor alpha (TNFα)69. 
They have high microbicidal activity and secrete large amounts of pro-inflammatory 
cytokines. Anti-inflammatory macrophages can be further divided into subtypes. One 
of these subtypes, develops when monocytes are exposed to IL-4 or IL-13, sometimes 
referred to as M2a, and these cells are considered anti-inflammatory due to their 
ability to down regulate pro-inflammatory stimuli39. Another subtype develops when 
monocytes are stimulated with IL-10, sometimes referred to as M2c, and downregulates 
pro-inflammatory cytokines and plays a role in tissue remodeling37. In earlier studies, 
it has been shown in vitro that bone-marrow derived macrophages48 and peritoneal 
macrophages49 secrete enzymes that may be responsible for cartilage degeneration. 
However, the direct effect of different macrophage phenotypes on cartilage is not clear. 
We hypothesized that pro-inflammatory macrophages exacerbate the progression of 
cartilage degeneration and anti-inflammatory macrophages can inhibit the progression 
of cartilage degeneration. Therefore, the direct effect of macrophage phenotypes on 
cartilage was assessed by culturing human articular cartilage with phenotype specific 
macrophage conditioned medium (MCM).
MateriaLs anD MethoDs
Preparation of subtype specific macrophage conditioned medium
Monocytes were isolated from a total of six buffy coats (males, 61±11 years; Sanquin 
blood bank, Amsterdam, the Netherlands) using Ficoll (GE Healthcare, Little Chalfont, 
UK) density gradient separation and CD14 magnetic-activated cell sorting microbeads 
(MACS; Miltenyi, Bergisch Gladbach, Germany) as previously described43. To prepare 
MCM, monocytes of three buffy coats were pooled, seeded in culture flasks at 500,000 
monocytes/cm2 and cultured in X-VIVO-15 (Lonza, Verviers, Belgium) containing 20% 
heat-inactivated fetal calf serum (FCS; Lonza), 50 µg/mL gentamicin (Gibco) and 1.5 
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µg/mL amphotericin B (Gibco) at 37°C and 5% CO2. Monocytes were stimulated with 
10 ng/mL Interferon-γ (IFNγ; PeproTech, Rocky Hill, NJ, USA) and 10 ng/mL Tumor 
Necrosis Factor-α (TNFα, PeproTech) to obtain pro-inflammatory M(IFNγ+TNFα) 
macrophages. The anti-inflammatory M(IL-4) subtype was obtained after stimulation 
with 10 ng/mL Interleukin-4 (IL-4; PeproTech). M(IL-10) was acquired by stimulation 
with 10 ng/mL IL-10 (PeproTech). After 48h, the medium used to differentiate the 
macrophages containing serum and stimuli was removed and the macrophages were 
washed twice with 0.9% NaCl (Sigma-Aldrich) before the addition of serum-free 
Dulbecco’s Modified Eagle Medium, low glucose (DMEM; Gibco) supplemented with 
1% Insulin-Transferrin-Selenium (ITS+ premix, Biosciences, New Jersey, USA), 50 µg/
mL gentamicin, 1.5 µg/mL amphotericin B) and 25 µg/mL L-ascorbic acid 2-phosphate 
(Sigma-Aldrich) to obtain MCM. After 24h, the MCM was harvested, centrifuged at 
200g and stored at -80°C until use. Non-conditioned DMEM supplemented with 1% 
Insulin-Transferrin-Selenium (ITS+ premix, Biosciences, New Jersey, USA), 50 µg/mL 
gentamicin, 1.5 µg/mL amphotericin B) and 25 µg/mL L-ascorbic acid 2-phosphate 
(Sigma-Aldrich) was also incubated, centrifuged and frozen to serve as control 
medium. Cells were harvested for DNA quantification using a modified CyQUANT 
assay (Invitrogen, Carlsbad, USA) as described previously80.
Cartilage explant culture in macrophage conditioned medium
Human articular cartilage was obtained with implicit consent as waste material from 
patients undergoing total knee replacement surgery for which the patients had the rights 
to refuse. This protocol was approved by the medical ethical committee of the Erasmus 
Medical Center, protocol number MEC-2004-322. Full thickness cartilage explants 
(ø=5mm) were harvested from macroscopically intact areas of the femoral condyles 
and tibia plateau and washed twice with 0.9% NaCl. Samples were pre-cultured for 
24h in DMEM, followed by culture with 50% MCM (n=6 cartilage donors, 68±7Y), or a 
combination of 50% M(IFNγ+TNFα) plus 50% M(IL-4) or M(IL-10) MCM (n=3 cartilage 
donors, 68±6 years). To simulate acute inflammation, cartilage explants (n=3 cartilage 
donors, 61±4 years) were pre-stimulated for 24h with 10 ng/mL IFNγ and 10 ng/mL 
TNFα, followed by culture with 50% MCM. The MCM was completed with 50% fresh 
medium to replenish potential nutrient depletion. Explants cultured in DMEM instead 
of MCM were included as controls. All MCM used for culture and analysis were frozen 
and thawed once. To account for the cell numbers by which the MCM was produced, 
the average DNA contents of all macrophage phenotypes were defined as 50% and 
the percentage MCM used in culture was adjusted for the DNA content per MCM 
phenotype as described previously5. The first MCM batch was used on explants of donor 
1-3 and the second batch was used on explants of donor 4-10. Donor demographics 
and culture conditions are presented in Table 3.1.
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Characterization of macrophage conditioned medium
To confirm macrophage polarization, IL-6, CCL18 and sCD163 were measured in the 
second MCM batch. In our previous work, we have characterized M(IFNγ+TNFα), 
table 3.1: Cartilage donor demographics and culture conditions
Donor gender age 24h pre-stimulation 48h treatment
no. of explants/
condition
1 Male 65 Non-stimulated
DMEM
M(IFNγ+TNFα) MCM
M(IL-4) MCM
M(IL-10) MCM 6
2 Male 65 Non-stimulated
DMEM
M(IFNγ+TNFα) MCM
M(IL-4) MCM
M(IL-10) MCM 3
3 Male 70 Non-stimulated
DMEM
M(IFNγ+TNFα) MCM
M(IL-4) MCM
M(IL-10) MCM 3
4 Female 59
Non-stimulated
IFNγ+TNFα stimulation
None (analyzed after 24h)
DMEM
M(IFNγ+TNFα) MCM
M(IL-4) MCM
M(IL-10) MCM 3
5 Female 78 Non-stimulated
DMEM
M(IFNγ+TNFα) MCM
M(IL-4) MCM
M(IL-10) MCM 3
6 Male 66
Non-stimulated
IFNγ+TNFα stimulation
None (analyzed after 24h)
DMEM
M(IFNγ+TNFα) MCM
M(IL-4) MCM
M(IL-10) MCM 3
7 Female 63 Non-stimulated
DMEM
M(IFNγ+TNFα) MCM
M(IL-4) MCM
M(IL-10) MCM
M(IFNγ+TNFα)+M(IL-4) MCM
M(IFNγ+TNFα)+M(IL-10) MCM 3
8 Female 66 Non-stimulated
DMEM
M(IFNγ+TNFα) MCM
M(IL-4) MCM
M(IL-10) MCM
M(IFNγ+TNFα)+M(IL-4) MCM
M(IFNγ+TNFα)+M(IL-10) MCM 3
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M(IL-4) and M(IL-10) primary human monocyte-derived macrophages based on gene 
expression and protein production5,43,68,69. IL-6 was found to be a good marker for 
M(IFNγ+TNFα), CCL18 for M(IL-4) and soluble CD163 (sCD163) for M(IL-10) which 
was also supported by others45,81. IL-6 (PeproTech), CCL18 (R&D Systems) and sCD163 
(PeproTech) protein concentrations were quantified in the MCM using enzyme-linked 
immunosorbent assays (ELISAs) according to manufacturer’s instructions. To check 
for possible nutrient depletion of the conditioned medium, glucose was measured. 
Glucose concentration was 0.83 g/L for M(IFNγ+TNFα) MCM, 0.93 g/L for M(IL-4) 
MCM, 0.92 g/L for M(IL-10) MCM and 1.0 g/L in non-conditioned medium. Since MCM 
was mixed 1:1 with fresh medium, the difference in glucose between the conditions 
was maximally 5.5% and considered negligible.
gene expression analysis of cartilage explants
mRNA isolation and cDNA synthesis of the cartilage explants were executed as described 
previously80. qPCR was performed on a Bio-Rad CFX96 Real-Time PCR Detection System 
(Bio-Rad, Hercules, CA, USA) to assess gene expression, matrix metalloproteinase-1 (MMP1; 
Fw: CTCAATTTCAC*TTCTGTTTTCTG; Rev: CATCTCTGTCGGCAAATTCGT; Probe: 
CACAACTGCCAAATGGGCTTGAAGC), MMP13 (Fw: AAGGAGCATGGCGACTTCT; 
Rev: TGGCCCAGGAGGAAAAGC; Probe: CCCTCTGGCCTGCGGCTCA), A 
disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS4; Fw: 
CAAGGTCCCATGTGCAACGT; Rev: CATCTGCCACCACCAGTGTCT; Probe: 
CATCTGCCACCACCAGTGTCT), ADAMTS5 (Fw: TGTCCTGCCAGCGGATGT; Rev: 
ACGGAATTACTGTACG*GCCTACA; Probe: ACGGAATTACTGTACGGCCTACA), 
aggrecan (ACAN), Collagen type II (COL2A1)80, Interleukin-1β (IL1B; Fw: 
CCCTAAACAGATGAAGTGCTCCTT; Rev: GTAGCTGGATGCCGCCAT), IL6, 
Tumor Necrosis Factor-α (TNFA)43, suppressor of cytokine signaling 1 (SOCS1; Fw: 
table 3.1: Cartilage donor demographics and culture conditions (continued)
Donor gender age 24h pre-stimulation 48h treatment
no. of explants/
condition
9 Male 58
Non-stimulated
IFNγ+TNFα stimulation
None (analyzed after 24h)
DMEM
M(IFNγ+TNFα) MCM
M(IL-4) MCM
M(IL-10) MCM 3
10 Female 75 Non-stimulated
DMEM
M(IFNγ+TNFα) MCM
M(IL-4) MCM
M(IL-10) MCM
M(IFNγ+TNFα)+M(IL-4) MCM
M(IFNγ+TNFα)+M(IL-10) MCM 3
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CCCTGGTTGTTGTAGCAGCTT; Rev: TTGTGCAAAGATACTGGGTATATGT) and SOCS3 
(Fw: TCGGACCAGCGCCACTT; Rev: CACTGGATGCGCAGGTTCT) were measured. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)43 was found stable and therefore 
further used as housekeeper gene. The nucleotide marked with an asterisk denotes a 
mismatch in the primer sequence. Gene expression levels of ADAMTS5 and MMP1 in OA 
cartilage were compared with those found in literature82 and this was similar. Furthermore, 
since all primer sequences were developed using NCBI BLAST according to a protocol to 
be specific for the gene of interest, we are confident that these primer-probe combinations 
are specific despite a single nucleotide mismatch. Amplification efficiency was confirmed 
using a dilution range of universal human cDNA and the efficiency was calculated using 
the following formula: 10^(-1/slope)-1. The primer was only approved if the slope was 
between -3.60 and -3.20, and if the efficiency was between 0.9 and 1.1. In case the 
primers were used for a SYBR GR assay, gel electrophoresis was conducted on the PCR 
products to ensure that no primer-dimers were formed and to confirm the product size. In 
case of a Taqman assay, a specific probe was designed to be used in combination with the 
primers to increase specificity. Finally, the following amplification protocol was used: 10 
min at 95°C, then 39 cycles of 95°C for 15s, 60°C for 60s, finishing with a melt curve from 
65°C to 95°C with 0.5°C increments of 5s. The relative expression of the genes of interest 
was determined by the 2−ΔCT formula.
nitric oxide (no) and glycosaminoglycan (gag) quantification
NO production was measured in the MCM and in the medium of the cartilage explants 
using Griess reagent (Sigma-Aldrich) as an indication of the degree of inflammation. The 
reaction was monitored at 540 nm using a spectrophotometer (VersaMax; Molecular 
Devices, Sunnyvale, USA). Sodium nitrite (NO2; Chem-lab, Zedelgem, Belgium) was 
used as standard.
GAG release in the MCM and in the medium of the explants was measured with 
a 1,9-Dimethylmethylene Blue assay (Sigma-Aldrich)83 as indication for cartilage 
degeneration. The reaction was monitored using a VersaMax at 530 and 590 nm. Shark 
chondroitin sulphate C (Sigma-Aldrich) was used as standard.
statistics
IBM SPSS 22.0 (IBM, New York, USA) and Microsoft Excel 2010 were used for 
calculations and statistical evaluation. Per donor, a minimum of three cartilage samples 
were used that were randomly divided per experimental condition. For PCR analysis, 
all samples were processed and analyzed individually. These values were used for 
statistical analysis. For the biochemical assays, the mean of a duplicate measurement 
per sample was used for statistical analysis. To take donor variability into account, a 
mixed linear model after log transformation was used. In the model, single or combined 
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phenotype specific MCM (e.g., M(IFNγ+TNFα), M(IL-4) and M(IL-10) MCM) and 
cartilage state (e.g., end-stage OA or pre-stimulated with IFNγ+TNFα) were defined 
as fixed factors, while the cartilage donor was considered as random factor. The tests 
were adjusted for multiple comparisons by a Bonferroni’s post hoc comparisons test. 
Differences were considered statistically significant for p<0.05.
resULts
Macrophage conditioned medium (MCM)
To confirm that the MCM was produced by different macrophage subtypes, IL-6, CCL18 
and sCD163 were measured. IL-6 protein concentration was high in M(IFNγ+TNFα) 
MCM, while undetectable (<62.5 pg/mL) in M(IL-4) and M(IL-10) MCM. CCL18 protein 
concentration was highest in M(IL-4) and lower in M(IFNγ+TNFα) and M(IL-10). 
sCD163 was high in M(IL-10) and undetectable (<156 pg/mL) in M(IFNγ+TNFα) and 
M(IL-4) (Figure 3.1). NO2 concentrations were undetectable (<1.25 µM) in MCM of 
all phenotypes, indicating that no NO was released into the MCM. Since NO was 
no longer produced by the macrophages, this could be used as a parameter to assess 
the induction of inflammation in cartilage. Average GAG concentrations in the MCM 
were 0.30 µg/mL for all phenotypes. These GAG concentrations were further reduced, 
since 50% MCM was used in the cultures. The final GAG concentrations in the MCM 
constituted for less than 0.04% of the average GAG release of cartilage explants, 
indicating that GAG production by macrophages can be considered negligible.
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

















	































	






CCL18




















	








sCD163
figure 3.1: Protein concentrations in MCM. IL-6, CCL18 and sCD163 protein concentrations of 
M(IFNγ+TNFα), M(IL-4) and M(IL-4) MCM. Bars represent the mean of a duplicate measurement. 
U.D: undetectable.
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Pro-inflammatory macrophages affect cartilage matrix genes and induce 
inflammation in osteoarthritic cartilage
To assess the direct effect of macrophages with different phenotypes on cartilage, OA 
cartilage was cultured with M(IFNγ+TNFα), M(IL-4) and M(IL-10) MCM and assessed 
by gene expression analysis, NO production and GAG release. Expression of IL1B, 
IL6, TNFA, SOCS1, MMP13 and ADAMTS5 was higher when cartilage was cultured 
with M(IFNγ+TNFα) MCM than when the cartilage was cultured with non-conditioned 
DMEM, while COL2A1 and ACAN were decreased. M(IL-4) MCM did not significantly 
affect any of the genes of interest, while IL1B and SOCS1 expression was higher in 
cartilage cultured with M(IL-10) than when cultured with DMEM (Figure 3.2A). NO 
production by the cartilage was statistically significantly increased when cultured with 
M(IFNγ+TNFα) and M(IL-10) MCM than when cultured with DMEM, while GAG release 
was significantly increased by the explants cultured with M(IFNγ+TNFα) (Figure 3.2B).
anti-inflammatory macrophages do not counteract pro-inflammatory 
processes in oa cartilage
To further investigate possible effects of anti-inflammatory macrophages directly on 
cartilage, OA cartilage was cultured with a combination of M(IFNγ+TNFα) MCM and 
M(IL-4) MCM or M(IL-10) MCM. No inhibiting effects were seen on gene expression 
levels of the genes of interest when the cartilage was cultured with the combinations 
of conditioned media of M(IFNγ+TNFα) and M(IL-4) or M(IFNγ+TNFα) and M(IL-10) 
compared to M(IFNγ+TNFα) only (Figure 3.3A). NO production by the cartilage 
when cultured with M(IFNγ+TNFα) was not counteracted by the addition of M(IL-4) 
or M(IL-10) MCM, as NO levels remained elevated (Figure 3.3B). Culture with single 
phenotype MCM or in combinations did not significantly affect GAG release of the 
cartilage explants (Figure 3.3C).
M(iL-4) and M(iL-10) do not inhibit acute inflammation or cartilage 
degeneration in stimulated cartilage
Since we could not detect a clear effect of M(IL-4) and/or M(IL-10) MCM directly on 
OA cartilage, we further investigated the potential effects of the anti-inflammatory 
macrophages. For this reason, acute inflammation was simulated in OA cartilage by 24h 
pre-stimulation with IFNγ+TNFα. After this pre-stimulation, expression of IL6, TNFA, 
SOCS1, MMP1 and ADAMTS4 was higher in stimulated cartilage than in unstimulated 
OA cartilage, while COL2A1 was lower (Figure 3.4A). NO production was higher 
in pre-stimulated cartilage than in unstimulated cartilage and GAG release was not 
significantly affected (Figure 3.4B). These data combined confirm that inflammation 
was induced, coupled with upregulation of genes that are associated with inflammation 
and matrix degradation, as well as suppression of collagen production. After the 
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24h pre-stimulation, the cartilage was cultured for another 48h in the presence of 
M(IFNγ+TNFα), M(IL-4) or M(IL-10) MCM. As expected, culturing the pre-stimulated 
cartilage with M(IFNγ+TNFα) MCM did not affect the genes of interest, indicating 
that pro-inflammatory macrophages did not further enhance the inflammation that 
was induced during the pre-stimulation period. Unexpectedly, after culturing the 
pre-stimulated cartilage explants with M(IL-4) MCM, only ACAN expression was 
affected and its expression was lower than when cultured in DMEM. Culturing cartilage 
B Total NO production Total GAG release
M(IFNγ+TNFα) MCM M(IL-4) MCM M(IL-10) MCMA
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figure 3.2: oa cartilage is significantly affected by pro-inflammatory macrophages. (a) 
Expression of genes encoding for inflammatory proteins: IL1B, IL6, TNFA, SOCS1 and SOCS3, 
genes associated with matrix degeneration: MMP1, MMP13, ADAMTS4 and ADAMTS5, and genes 
associated with matrix components: ACAN and COL2A1 of OA cartilage cultured with MCM. 
The expression is shown relative to the expression of cartilage cultured with non-conditioned 
DMEM control medium represented by the dotted line. Data of all samples presented as dot plots 
including the grand median for n=6 cartilage donors with three samples per donor (six samples 
for donor 1). (b) NO production by cartilage after culture with MCM as an indication of the 
inflammatory state and GAG release as an indication of cartilage degeneration after culture with 
MCM. Data is presented relative to the NO production and GAG release of cartilage cultured 
in non-conditioned DMEM control medium represented by the dotted line for n=6 cartilage 
donors with three samples per donor (six samples for donor 1 and 2). Statistical evaluation was 
conducted with a linear mixed model after log transformation followed by a Bonferroni’s post 
hoc test. Abbreviations: IL1B: Interleukin-1β; IL6: Interleukin-6; TNFA: Tumor Necrosis Factor-α; 
SOCS1, -3: Suppressor of cytokine signaling 1, -3; MMP1, -13: matrix metalloproteinase-1, -13; 
ADAMTS4,-5: A disintegrin and metalloproteinase with thrombospondin motifs-4, -5; ACAN: 
aggrecan; COL2A1: collagen type II
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figure 3.3: M(iL-4) and M(iL-10) macrophages do not counteract the inflammatory effects of 
M(ifnγ+tnfα) on oa cartilage. (a) Gene expression levels of OA cartilage after culture with 
single phenotype MCM or a combination of phenotypes. Figures B and C on next page.
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with M(IL-10) did not affect any of the genes of interest (Figure 3.5A). NO production 
and GAG release were unaffected by the conditioned medium of either macrophage 
phenotype (Figure 3.5B).
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figure 3.4: stimulation of oa cartilage with ifnγ+tnfα as a cartilage inflammatory model. To 
simulate acute inflammation, OA cartilage explants were pre-stimulated for 24h with IFNγ+TNFα. 
(a) The effect of IFNγ+TNFα pre-stimulation on gene expression levels, (b) NO production and 
release of GAG. Gene expression levels are shown relative to the expression of OA cartilage 
explants cultured in DMEM as represented by the dotted line. Data of all samples is presented in 
dot plots including the grand median for n=3 cartilage donors with three samples for each donor. 
For statistical evaluation, a mixed linear model after log transformation was used followed by a 
Bonferroni’s post hoc test.
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figure 3.3: M(iL-4) and M(iL-10) macrophages do not counteract the inflammatory effects 
of M(ifnγ+tnfγ) on oa cartilage (Continued). (b) NO production and (C) GAG release of 
OA cartilage after culture with single phenotype MCM or a combination of phenotypes. For the 
cultures with single phenotype MCM, the MCM was completed 1:1 with fresh DMEM to reach 
50% MCM. For the cultures with combined phenotype MCM, 50% of each phenotype was used 
in the cultures. For the control medium, previously frozen non-conditioned DMEM was combined 
1:1 with fresh DMEM. Data of all samples presented in dot plots including the grand median for 
n=3 cartilage donors with three samples per donor. Statistical evaluation was conducted with a 
linear mixed model after log transformation followed by a Bonferroni’s post hoc test.
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DisCUssion
We have shown in this study that pro-inflammatory macrophages exacerbate 
processes involved in degeneration of OA cartilage and induce inflammation, while 
anti-inflammatory macrophages do not directly affect OA cartilage, or inhibit effects 
of pro-inflammatory macrophages on cartilage. This suggests that inhibition of 
pro-inflammatory macrophages or enhancing the performance of anti-inflammatory 
macrophages may be relevant targets to consider when developing therapies that are 
aiming at inhibiting cartilage degeneration.
Since inflammation plays an important role in the development and progression 
of OA, development of therapies focusing on synovial inflammation is increasing. 
However, in vitro studies that acknowledge macrophage-mediated inflammation in 
their culture models did not consider the spectrum of phenotypes that may be present 
B Total NO production Total GAG release
M(IFNγ+TNFα) MCM M(IL-4) MCM M(IL-10) MCMA
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figure 3.5: the effect of anti-inflammatory macrophages on acute inflamed cartilage. To assess 
potential effects of anti-inflammatory macrophages, acute inflamed cartilage (i.e. pre-stimulated 
with IFNγ+TNFα) was cultured with MCM. (a) Expression levels of IFNγ+TNFα pre-stimulated 
cartilage cultured with MCM. Expression is shown relative to the expression of pre-stimulated 
cartilage explants cultured in non-conditioned DMEM without IFNγ+TNFα as represented by 
the dotted line. (b) NO production and GAG release by IFNγ+TNFα pre-stimulated cartilage 
after culture with MCM relative to the controls cultured in DMEM as represented by the dotted 
line. Data of all samples is presented in dot plots including the grand median for n=3 cartilage 
donors with three samples for each donor. For statistical evaluation, a mixed linear model after 
log transformation was used followed by a Bonferroni’s post hoc test.
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in in vivo situations48,49,84. To our knowledge, we are the first to describe the direct 
effects of specific macrophage phenotypes on human articular cartilage. Although 
the M1/M2-classification of macrophages is mainly applicable to in vitro models, by 
generating subtypes of M2 macrophages, we aimed to include a range of macrophages 
phenotypes that mimic in vivo situations. The macrophage phenotypes were confirmed 
by the protein secretion profiles of IL-6, CCL18 and sCD163. Since these three proteins 
are also found in the synovial fluid of OA patients85-89, this suggests that macrophages 
of various phenotypes may be linked to OA pathogenesis and progression.
In this study, M(IFNγ+TNFα) MCM affected OA cartilage by inhibiting genes associated 
with matrix production, upregulation of matrix degenerating genes and induction of 
inflammation. This was expected and in line with previous work, where we have shown 
that synovial macrophages and monocyte-derived pro-inflammatory macrophages 
negatively affected chondrogenesis of mesenchymal stem cells5,55. In contrast, M(IL-4) 
did not affect OA cartilage, while M(IL-10) seemed to induce inflammation to some 
extent, although less intense than M(IFNγ+TNFα). Both M(IL-4) and M(IL-10) were 
unable to counteract the pro-inflammatory effects of M(IFNγ+TNFα) MCM, since NO 
levels were not reduced when M(IFNγ+TNFα) MCM was combined with M(IL-4) or 
M(IL-10) and expression levels of the majority of the genes of interest, were not rescued 
by M(IL-4) and M(IL-10) MCM. This was somewhat unexpected since it was demonstrated 
earlier that monocytes stimulated with macrophage colony-stimulating factor (M-CSF), 
enhanced chondrogenesis in vitro90. This discrepancy could be explained by the fact 
that processes during chondrogenesis are different than processes occurring in mature, 
degenerating cartilage. Furthermore, the anti-inflammatory macrophages in our study 
were not polarized by M-CSF, but with IL-4 and IL-10. Even when extra inflammation 
was induced in OA cartilage, M(IL-10) MCM in our study did not have an effect on any 
of the genes of interest. M(IL-4) MCM on the other hand, reduced ACAN expression 
of the stimulated cartilage to some extent. When M1 and M2 MCM were combined, 
anti-inflammatory macrophages were also unable to inhibit the inflammatory effects 
of M(IFNγ+TNFα) MCM. In the current study, a concentration of 50% MCM was used. 
Although with this concentration M(IFNγ+TNFα) MCM affected OA cartilage, while 
M2 MCM did not have a clear effect, it cannot be ruled out that higher concentrations 
of M2 MCM would have affected cartilage. Our results suggest that the products 
of anti-inflammatory macrophages only may not be sufficient or potent enough for 
directly suppressing inflammation in cartilage in this system, but interaction between 
macrophages of different phenotypes may be required to initiate biological actions. 
One should therefore realize that other in vitro or in vivo models may be needed 
to further investigate the mechanisms of the role of macrophage subtypes on either 
protecting cartilage or inducing degeneration and inflammation. A second limitation of 
our study is that the macrophage phenotypes were characterized based on three main 
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factors, which were shown in our previous work68 to be good markers for our generated 
phenotypes. More extensive characterization or profiling of soluble macrophage factors 
may help to pinpoint which active factor in M(IFNγ+TNFα) MCM actually affected the 
cartilage. That knowledge may then be used to develop targeted therapies.
This in vitro model enabled us to study the direct effect of factors secreted by 
macrophages of different phenotypes on cartilage inflammation and degeneration. The 
use of human cartilage explants and primary human macrophages makes translation of 
the results to the clinical situation more realistic. The variability of the cartilage between 
donors and within samples of the same donors is, however, an inevitable disadvantage 
of the use of human cells and tissues. Although macroscopically preserved cartilage was 
used in the experiments, differences in local degeneration of the used tissue resulted in 
variable baseline levels of GAG, varying chondrocyte viability and inflammatory state, 
as seen by the high variability within donors in our experiments. In this model, MCM 
had clear effects on production of NO. In the majority of our experiments, however, 
GAG release was unaffected by MCM. The release of GAG is influenced by multiple 
processes such as production and breakdown. Longer culture periods may be necessary 
to be able to observe effects on GAG release. Though an effect on GAG release was 
not detected, processes associated with cartilage degeneration were initiated by the 
macrophages, as indicated by decreased levels of ACAN and increased gene expression 
of cartilage degrading enzymes.
Based on the data of this study, management of the behavior of synovial macrophages 
may seem a suitable approach to prevent cartilage degeneration. Additionally, the 
importance of the role of macrophages during wound healing and tissue regeneration 
in vivo models has been reported by others91,92. Though we were unable to show a 
direct protective effect of anti-inflammatory macrophages on cartilage, we believe that 
this phenotype should not be completely disregarded, since an obvious interplay and 
balance between macrophage phenotypes and other cell types may contribute to their 
regenerative or protective capacity. More studies will be needed to fully understand this 
mechanism prior to clinical application.
ConCLUsion
M(IFNγ+TNFα) pro-inflammatory macrophages have a prominent direct effect on OA 
cartilage while M(IL-4) and M(IL-10) do not inhibit the inflammatory and degenerative 
effects of M(IFNγ+TNFα). This knowledge may be taken into consideration when 
developing therapies aiming at inhibition of cartilage degeneration, by inhibiting pro-
inflammatory macrophages or stimulating anti-inflammatory macrophages.


5Guiding synovial inflammation by macrophage phenotype modulation: an in vitro study towards a therapy 
for osteoarthritis
Osteoarthritis Cartilage. 2016;24(9):1629-38.
Lizette Utomo
Gerjo J.V.M. van Osch
Yves Bayon
Jan A.N. Verhaar
Yvonne M. Bastiaansen-Jenniskens
Chapter 5
70
abstraCt
Objective: The aims of this study were to modulate inflammation in synovial explants 
with the compounds: dexamethasone, rapamycin, bone morphogenetic protein 7 
(BMP-7) and pravastatin, and to investigate the modulatory capacity of the compounds 
on specific macrophage phenotypes.
Design: Synovial explants from osteoarthritis (OA) patients were treated with 10−6M 
dexamethasone, 100 ng/mL rapamycin, 500 ng/mL BMP-7 or 50 µM pravastatin. Half 
of the explants were pre-stimulated with IFNγ+TNFα to simulate acute inflammation. 
Inflammatory state of the synovium was assessed with gene expression analysis. Primary 
human monocytes were isolated and stimulated towards macrophage phenotypes 
M(IFNγ+TNFα), M(IL-4) and M(IL-10) with the respective cytokines, followed by 
treatment with the compounds.
Results: Dexamethasone had an anti-inflammatory effect on IFNγ+TNFα 
stimulated and osteoarthritic synovium, likely due to suppression of pro-inflammatory 
M(IFNγ+TNFα) macrophages while enhancing anti-inflammatory M(IL4) and M(IL10) 
macrophages. Rapamycin and BMP-7 further enhanced inflammation in stimulated 
synovium, but rapamycin did not have a clear effect on non-stimulated synovium. 
Rapamycin suppressed M(IL-4) and M(IL-10) macrophages without affecting 
M(IFNγ+TNFα). BMP-7 suppressed M(IFNγ+TNFα) and enhanced M(IL-10) in the 
macrophage cultures. Pravastatin did not affect synovium, but enhanced M(IL-10).
Conclusions: These data indicate that macrophage phenotype modulation can be 
used to guide joint inflammation and thereby contribute to the development of new 
therapies to delay the progression of OA. The varying effects of the compounds on 
synovium of different degrees of inflammation, indicate that the modulatory capacity 
of the compounds depends on OA stage and underlines the importance of identifying 
this stadium for adequate treatment.
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introDUCtion
Osteoarthritis (OA), a chronic degenerative disease affecting the whole joint, is 
characterized by erosion of articular cartilage and synovial inflammation. Macrophages, 
along with fibroblasts, reside in the synovial lining of joints. These cells can become 
activated by stimuli from their microenvironment, a process that results in a spectrum 
of phenotypes47. This spectrum ranges from pro-inflammatory (M1) macrophages, 
induced by stimuli such as interferon (IFN), tumor necrosis factors (TNFs)125 or 
lipopolysaccharides (LPS)45, to anti-inflammatory macrophages (M2), which can 
be further divided into specific subtypes depending on their stimuli such as IL-4 or 
IL-1045. Because of their importance in diseases and homeostasis, macrophages are 
frequently the focus of development of new interventions and treatment strategies126. 
Early in vivo studies have shown that depletion of phagocytic synovial lining cells, 
resulted in less influx of polymorphonuclear neutrophils, reduced proteoglycan 
degradation and reduced chondrocyte death of cartilage after induction of collagen 
induced arthritis (CIA)127 . It was suggested that monocytes/macrophages are mainly 
responsible for this cartilage damage128. Moreover, osteophyte formation was also 
reduced after depletion of synovial macrophages in an OA mouse model51. The fact that 
high levels of pro-inflammatory cytokines were found in synovial fluid of OA joints and 
after trauma93,94, together with the role macrophages seem to play in the development 
of OA and other inflammatory joint diseases, led to the hypothesis that a potentially 
specific strategy to control inflammation would be modulating the polarization state 
of macrophages. Therefore, the aim of this study was to guide synovial inflammation 
with four compounds representing commonly used classes of drugs in the clinics, 
that may have the potential to modulate macrophage phenotype: dexamethasone, 
rapamycin, bone morphogenetic protein 7 (BMP-7) and pravastatin. Dexamethasone 
is a corticosteroid with well-known anti-inflammatory effects129 and is used to treat 
numerous inflammatory-based diseases. Rapamycin, known by its non-propriety name 
sirolimus, is an immunosuppressive commonly used in transplantation medicine130. 
It inhibits T-cell activation by inhibiting signal transduction via mammalian target of 
rapamycin (mTor)131. BMP-7 is a member of the transforming growth factor beta (TGF-β) 
superfamily and is clinically used in orthopedic studies and applications, such as long 
bone non-union fractures132,133. Additionally, it has been shown that BMP-7 directed 
the polarization of THP-1 monocytes into an anti-inflammatory state134. Pravastatin is a 
member of the statins, a group of cholesterol synthesis inhibitors with a broad spectrum 
of effects, including anti-inflammatory effects135. Since all compounds are known to 
affect inflammatory processes, we investigated their effects on synovium of different 
degrees of inflammation. For this reason, OA synovium was additionally stimulated 
with IFNγ+TNFα to simulate acute inflammation. Furthermore, to examine the 
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modulatory effects of the compounds on macrophage phenotypes, human monocyte-
derived macrophages were polarized to specific phenotypes and treated with the same 
compounds.
MateriaLs anD MethoDs
Modulation of synovium
To examine the effect of stimulation with IFNγ+TNFα, synovial tissue was obtained 
from OA patients (n=4, 60±13Y) undergoing total knee replacement surgery. The 
synovium was washed twice with 0.9% NaCl (Sigma-Aldrich, St. Louis, USA) and cut 
into pieces of 30-35 mg wet weight. To simulate acute inflammation93,94, the explants 
were cultured for 24h with 10 ng/mL Interferon-γ (IFNγ; PeproTech, Rocky Hill, NJ, 
USA) and 10 ng/mL Tumor Necrosis Factor-α (TNFα, PeproTech) in medium (Dulbecco’s 
Modified Eagle Medium, low glucose (DMEM; Gibco, Carlsbad, USA) supplemented 
with 1% Insulin-Transferrin-Selenium (ITS+ Premix, Corning, New York, USA), 50 µg/
mL gentamicin (Gibco), 1.5 µg/mL amphotericin B (Fungizone; Gibco) and 25 µg/mL 
ʟ-ascorbic acid 2-phosphate (Sigma-Aldrich)). After 24h of stimulation, the synovial 
explants were harvested and stored at -80°C until assessment for their inflammatory 
state after stimulation using gene expression analysis. To examine the effect of the 
compounds, synovial explants of other patients (n=4; 63±3Y) were pre-cultured for 24h 
with or without IFNγ+TNFα as described above to obtain acute inflamed synovium. 
Then, 10−6 M dexamethasone (Sigma-Aldrich), 100 ng/mL rapamycin (R&D Systems, 
Minneapolis, USA), 500 ng/mL BMP-7 (PeproTech), or 50 µM pravastatin (Sigma-
Aldrich) were added to the medium and the explants were cultured for an additional 
3 days. Doses were chosen based on literature134,136-141. Dimethyl sulfoxide (DMSO; 
Sigma-Aldrich) was used as vehicle for dexamethasone and rapamycin and the final 
DMSO concentration in the cultures was 0.01%. Donor demographics and culture 
conditions are shown in Table 5.1. The medium including compounds and stimuli 
was refreshed 24h prior to harvest and the explants were stored at -80°C until further 
processing for gene expression analysis.
Monocyte isolation, stimulation and macrophage modulation
Primary human monocytes were polarized to specific macrophage phenotypes and 
cultured with the compounds. Monocytes were isolated by Ficoll density gradient 
separation and CD14+ selection as described previously43 from human buffy coats of 
male donors, 52±14Y (Sanquin Blood bank, Amsterdam, the Netherlands). For every 
experiment, monocytes were pooled from at least two donors and plated in monolayers 
in 48-well plates (Corning Costar, NY, USA) at a density of 500,000 monocytes/cm2 in 
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X-VIVOTM 15 medium (Lonza, Verviers, Belgium) supplemented with 20% heat-inactivated 
fetal calf serum (FCS; Lonza), 50 µg/mL gentamicin and 1.5 µg/mL amphotericin B. To 
model a range of phenotypes of activated macrophages, the monocytes were stimulated 
1 h after plating with 10 ng/mL IFNγ and 10 ng/mL TNFα (from now on referred to as 
M(IFNγ+TNFα)), 10 ng/mL Interleukin-4 (IL-4; PeproTech), to obtain M(IL-4) or 10 ng/mL 
IL-10 (PeproTech) to obtain M(IL-10)45,125. The macrophages were cultured and stimulated 
for 3 days at 37°C and 5% CO2. After the stimulation period, the polarized macrophages 
were treated either with 10−6 M dexamethasone, 100 ng/mL rapamycin, 500 ng/mL 
BMP-7 or 50 µM pravastatin and cultured for an additional 3 days. The final DMSO 
concentration used in the cultures was 0.01%. The medium including compounds and 
table 5.1: Donor demographics and culture conditions of synovial explants
Donor gender age non-stimulated/ifnγ+tnfα stimulated Compound treatment
1 female 42
Non-stimulated
IFNγ+TNFα stimulation None (analyzed after 24h)
2 female 74
Non-stimulated
IFNγ+TNFα stimulation None (analyzed after 24h)
3 male 65
Non-stimulated
IFNγ+TNFα stimulation None (analyzed after 24h)
4 male 65
Non-stimulated
IFNγ+TNFα stimulation
None (analyzed after 24h)
DMEM (vehicle control)
DMSO (vehicle control)
Dexamethasone
Rapamycin
BMP-7
Pravastatin
5 male 65
Non-stimulated
IFNγ+TNFα stimulation
DMEM (vehicle control)
DMSO (vehicle control)
Dexamethasone
Rapamycin
BMP-7
Pravastatin
6 male 65
Non-stimulated
IFNγ+TNFα stimulation
DMEM (vehicle control)
DMSO (vehicle control)
Dexamethasone
Rapamycin
BMP-7
Pravastatin
7 male 64
Non-stimulated
IFNγ+TNFα stimulation
DMEM (vehicle control)
DMSO (vehicle control)
Dexamethasone
Rapamycin
BMP-7
Pravastatin
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stimuli was refreshed 24h prior to harvest. After culture, the medium was collected, 
centrifuged at 200 x g to remove detached cells, and the supernatants were stored at 
-80ºC until cytokine measurements. The cells were harvested in PBS/0.1% Triton X-100 
(Sigma-Aldrich) for DNA quantification or in RLT lysis buffer/1% β-mercaptoethanol 
(Qiagen, Hilden, Germany/Sigma-Aldrich) for mRNA isolation.
gene expression analysis
mRNA isolation, cDNA synthesis and PCR analysis were performed as described 
previously80. Gene expression of Interleukin-6 (IL6), Interleukin-1β (IL1B), Tumor 
Necrosis Factor-α (TNFA), chemokine (C-C motif) ligand 18 (CCL18), Interleukin-1 
Receptor Antagonist (IL1RA), Mannose receptor, C type 1/CD206 (MRC1/CD206), 
cluster of differentiation 163 (CD163), Toll-Like-Receptor 4 (TLR4), and Transforming 
Growth Factor β1 (TGFB1) was evaluated. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), hypoxanthine phosphoribosyltransferase 1 (HPRT1) and ubiquitin C (UBC) 
were all tested as housekeepers, where GAPDH was found the most stable (data not 
shown) and was therefore further used as normalization for the genes of interest. The 
amplification efficiency of all primers (Supplementary Table S5.1) was between 0.90 
and 1.05 and the relative expression was determined by the 2−ΔCT formula.
Quantification of cytokine production
Production of IL-6, CCL18 and soluble CD163 (sCD163) by the macrophages was 
quantified by enzyme-linked immunosorbent assays (ELISAs) according to the 
manufacturer’s instructions of the human IL-6 ELISA Development Kit (PeproTech), 
human CCL18 DuoSet Development Kit (R&D Systems) and human soluble CD163 
DuoSet Development Kit (R&D Systems). As an indication of the number of cells in the 
monolayers and to normalize cytokine production, the DNA content of the monolayers 
was measured using a modified CyQUANT assay (Invitrogen, Carlsbad, USA) as described 
previously80.
M1/M2-index calculation
An M1/M2-index was calculated based on the expression of the pro-inflammatory 
(M1) genes (IL6, IL1B and TNFA) and the anti-inflammatory (M2) genes (CCL18, IL1RA, 
CD206 and CD163). The mean of the relative expression of M1 genes per sample to the 
overall M1 gene expression of all samples, was divided over the mean of the relative 
expression of M2 genes per sample to the overall M2 gene expression of all samples43.
statistics
MS Excel 2010 and PASW Statistics 21.0 (SPSS Inc., Chicago, USA) were used for 
statistical evaluation. To take into account the variability between donors, a mixed 
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linear model after log transformation was used, followed by a Bonferroni’s post hoc 
comparisons test. For the synovial explant experiments, inflammation state of the 
synovium (i.e., stimulation with IFNγ+TNFα) and donor were defined as random 
factors, while compound treatment was defined as a fixed factor. For the macrophages 
cultured in monolayers, polarization together with compound treatment were defined 
as fixed factors, while individual experiments were considered as random factors in the 
model. Differences were considered to be statistically significant for P<0.05.
resULts
stimulation of osteoarthritic synovium leads to a difference in gene 
expression profiles
To investigate the modulatory capacity of the compounds on synovium of different 
degrees of inflammation, a culture model with or without IFNγ+TNFα stimulation was set 
up. Gene expression of IL6, IL1B, TNFA, CCL18 and IL1RA was higher in OA synovium 
stimulated with IFNγ+TNFα than of synovium without stimulation when cultured in 
DMEM only (Figure 5.1A). The expression profile of IFNγ+TNFα stimulated synovium 
resulted in a higher M1/M2-index (Figure 5.1B), indicating that acute inflammation was 
indeed induced in the culture model.
Dexamethasone, rapamycin, bMP-7 and pravastatin can modulate the 
gene expression profile of synovium
In IFNγ+TNFα stimulated OA synovium treated with dexamethasone, IL1B, IL6, TNFA, 
IL1RA and CCL18 were lower than in the stimulated synovium cultured in DMSO 
control medium, while CD206 and CD163 were higher. This expression profile resulted 
in a lower M1/M2-index than in the controls. Treatment with rapamycin increased IL6, 
while lowering CCL18 in stimulated synovium. This resulted in a higher M1/M2-index 
than in the DMSO controls. BMP-7 lowered expression of IL1RA compared to the 
DMEM controls, while pravastatin did not affect any of the genes of interest. For both 
BMP-7 and pravastatin, this expression profile resulted in a higher M1/M2-index than 
in the controls (Figure 5.2A).
In non-stimulated OA synovium treated with dexamethasone, IL1B was lower than in 
non-stimulated synovium cultured in DMSO control medium, while CD163 was higher, 
eventually resulting in a lower M1/M2-index. Rapamycin did not affect the genes of 
interest, but the overall inflammation was reduced as indicated by a lower M1/M2-index. 
BMP-7 lowered IL1B and increased CCL18, resulting in a lower M1/M2-index than in 
the DMEM controls. Pravastatin did not affect the genes of interest and did not alter the 
overall inflammatory state of non-stimulated synovium (Figure 5.2B).
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Characterization and modulation of primary polarized macrophages
To assess the modulatory capacity of the compounds on specific macrophage phenotypes, 
primary monocyte-derived macrophages were polarized towards specific macrophage 
phenotypes and treated with the compounds. Without treatment, M(IFNγ+TNFα) had 
high expression levels of IL6, IL1B, TNFA, IL10 and TFGB1 and high protein production 
of IL-6. M(IL-4) expressed high levels of CC18, IL1RA and CD206 and had high CCL18 
protein production. M(IL-10) had higher expression of CD206 than M(IFNγ+TNFα), 
but was lower than in M(IL-4). CD163 was mainly expressed in anti-inflammatory 
macrophages and expression levels were higher in M(IL-10) than in M(IL-4). sCD163 
protein production was high in M(IL-10) (Figure 5.3A and B). This confirmed that 
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figure 5.1: gene expression profile of osteoarthritic synovium with and without ifnγ+tnfα 
stimulation. (a) Expression of genes encoding for pro-inflammatory proteins (IL1B, IL6 and 
TNFA) and genes encoding for anti-inflammatory proteins (IL1RA, CCL18, CD206 and CD163) 
relative to the expression of Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (b) An M1/
M2-index based on expression of all measured pro-inflammatory genes and anti-inflammatory 
genes to provide an overall assessment of the inflammatory state of the synovium with or without 
IFNγ+TNFα stimulation. Data is presented as boxplots with whiskers from minimum to maximum 
for n=4 donors in triplicate.
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stimulation with IFNγ+TNFα resulted in pro-inflammatory macrophages and IL-4 or 
IL-10 stimulation resulted in the development of anti-inflammatory macrophages of 
distinct phenotypes. As the IL-6, CCL18 and sCD163 protein production patterns were 
also specific for our generated phenotypes, we decided to use these three proteins 
as read-out parameters for detailed examination of the effects of the compounds on 
macrophages in monolayer.
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figure 5.2: Modulation of stimulated and non-stimulated osteoarthritic (oa) synovial tissue. 
(a) Gene expression profiles of IFNγ+TNFα stimulated OA synovium, and (b) non-stimulated OA 
synovium after treatment with dexamethasone, rapamycin, BMP-7 or pravastatin relative to the 
expression levels of the vehicle controls as represented by the dotted line. 0.01% DMSO was 
used as vehicle control for dexamethasone and rapamycin and X-VIVO medium was used as 
vehicle control for BMP-7 and pravastatin. The M1/M2-index provides an overview of the overall 
inflammatory state of the synovial tissue after treatment with the compounds based on expression 
of all the measured pro-inflammatory genes and anti-inflammatory genes. Data is presented in 
boxplots with whiskers from minimum to maximum for n=4 donors in triplicate.
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Interestingly, after treatment with dexamethasone, IL-6 production by the 
M(IFNγ+TNFα) was decreased, while production levels were maintained in M(IL-4) 
and M(IL-10). Production of CCL18 by M(IFNγ+TNFα) was maintained as well, 
whereas CCL18 production was increased in M(IL-4) and M(IL-10). sCD163 
production was highly increased in all three macrophage phenotypes after treatment 
with dexamethasone (Figure 5.4A). Treatment with rapamycin lowered the IL-6 and 
CCL18 production of M(IL-4), CCL18 production of M(IL-10) and sCD163 production 
of M(IL-4) (Figure 5.4B). BMP-7 treatment did not have an effect on the IL-6, CCL18 and 
sCD163 protein production of M(IFNγ+TNFα) and M(IL-4), while CCL18 and sCD163 
production was increased in M(IL-10) (Figure 5.4C). Pravastatin did not have an effect 
on the IL-6 and CCL18 production of either macrophage phenotypes, yet sCD163 was 
higher in M(IL-10) than in the untreated controls (Figure 5.4D).
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figure 5.3: Characterization of primary human macrophages stimulated with ifnγ and tnfα 
(M(ifnγ+tnfα)), iL-4 (M(iL-4)) and iL-10 (M(iL-10)). (a) Gene expression profile relative to 
GAPDH expression and (b) protein production of IL-6, CCL18 and sCD163 corrected for amount 
of DNA. Data is shown as mean ± SD for n=3 donors in 5-fold. The error bars represent the 
variation between donors.
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figure 5.4: Modulation of primary polarized macrophages. IL-6, CCL18 and sCD163 protein 
production of M(IFNγ+TNFα), M(IL-4) and M(IL-10) macrophages after modulation with 
a) dexamethasone, b) rapamycin, C) BMP-7, and D) pravastatin. Data is presented for n=3 
independent experiments in triplicate as boxplots with whiskers from minimum to maximum and 
relative to the compound vehicle controls represented as a dotted line. 0.01% DMSO was used 
as vehicle control for dexamethasone and rapamycin and X-VIVO medium was used as vehicle 
control for BMP-7 and pravastatin.
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DisCUssion
In this study, we have shown that the overall inflammatory state of synovial explants can 
be modulated by dexamethasone, rapamycin, and BMP-7. Because macrophages play 
a crucial role in inflammatory processes that contribute to inflammation, phenotype 
modulation can be used to control synovial inflammation, and subsequently may also 
inhibit the progression of post-traumatic OA.
Nowadays, many compounds are being tested for their anti-inflammatory effects 
in vitro as potential new interventions for OA. However, completely suppressing 
inflammation, either via macrophages or by directly inhibiting cytokines, may not 
be the most successful method to treat OA, as inflammation to a certain extend is 
required for proper wound healing142. Since the composition of synovial tissue varies at 
different stages of OA2 and even between patients, we can assume that the composition 
of macrophage phenotypes in the synovium also differs, which was indicated in our 
previous work5. To our knowledge, we are the first to show modulation of synovium 
of different degrees of inflammation using compounds that are already clinically 
applied. In addition, we showed that these compounds target specific macrophage 
phenotypes by either enhancing or suppressing their function. Our culture model using 
human synovium allowed us to study in vitro the effects of the compounds on synovial 
macrophages in their natural microenvironment. We are aware that we cannot rule out 
the possibility that by treating the explants with the compounds, fibroblasts or other cells 
present in the synovium were also affected by the compounds. Therefore, we compared 
the modulatory effects of the compounds on the entire synovial explants in terms of 
change in overall synovial inflammation, with their effect on different phenotypes of 
macrophages cultured in monolayers. Macrophages, once migrated into tissue, are in 
an activated state. With the polarization of M(IFNγ+TNFα), M(IL-4) and M(IL-10), we 
aim to model this range of phenotypes. Our aim was to modulate already polarized 
macrophages in synovial tissue and not to intervene with the process of polarization 
from monocyte to macrophage. Therefore, assessment of the effects of the compounds 
on unstimulated macrophages is beyond the scope of this study. Additionally, we have 
shown that compounds that were initially known for their anti-inflammatory effect, can 
either behave in a pro-inflammatory or anti-inflammatory manner and that the behavior 
of the compounds differs and depends on the macrophage phenotypes present in the 
tissue that is treated. The specific modulatory effects of the compounds on synovium 
and macrophages could provide valuable insights for the development of specialized 
therapies aiming at modulation of specific macrophage phenotypes.
In our study, dexamethasone had an anti-inflammatory effect on synovium and 
suppressed the pro-inflammatory macrophage phenotype, while enhancing the anti-
inflammatory macrophages. Since CD163 expression can be assumed as a marker 
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for M(IL-10), these data combined suggests that dexamethasone has the capacity to 
modulate synovial tissue and to specifically enhance the macrophage phenotypes 
resembling M(IL-10). The effect of dexamethasone on macrophages was shown earlier to 
vary depending on macrophage origin, as phagocytic activity in alveolar macrophages 
was induced more abundantly than in peritoneal macrophages143. The difference in 
anti-inflammatory capacity per macrophage source suggests that treatment with 
dexamethasone may result in responses that differ according to macrophage type or 
origin. Intra-articular delivery of dexamethasone was shown to have chondroprotective 
effects and reduced inflammation in a post-traumatic OA animal model144. This could 
be explained by the fact that dexamethasone enhanced M(IL-10), which was seen in 
our present study, as well as of others81, on gene expression level and by increased 
levels of sCD163 in the macrophage cultures. Although this subtype expressing CD163 
has been described as the tissue repair phenotype38, is has also been associated with 
(chronic) inflammatory diseases145,146. Additionally, CD163 expressing macrophages 
induced by intra-articular injection of triamcinolone acetonide, also a corticosteroid, 
have been linked as well with the prevention of osteophyte formation in an OA rat 
model147.
Rapamycin exerted an overall pro-inflammatory effect on IFNγ+TNFα stimulated 
synovium in this study, while the effect on non-stimulated OA synovium was less clear 
as no differences in expression levels were seen of any of the genes of interest. Our 
data indicated that the increase of inflammation of stimulated synovium in response to 
rapamycin was likely due to suppression of anti-inflammatory macrophages, without 
affecting the pro-inflammatory macrophages, as indicated by reduced IL-6, CCL18 and 
sCD163 protein production in the anti-inflammatory macrophages, while these levels 
were maintained in M(IFNγ+TNFα) after treatment with rapamycin. This was in line with 
an earlier study, where inhibition of the mTOR signaling pathway was shown to regulate 
macrophage polarization. Murine macrophages in which Tsc1 was specifically deleted, 
and therefore mTOR complex 1 constitutively activated, were unable to polarize towards 
M2, while the pro-inflammatory response to LPS was enhanced. Treatment of these 
macrophages with rapamycin rescued this M2 polarization deficiency136. Furthermore, 
rapamycin seemed to shift the polarization of human macrophages towards a pro-
inflammatory phenotype in vitro148. BMP-7 had an overall pro-inflammatory effect on 
IFNγ+TNFα stimulated synovium, while an anti-inflammatory effect on non-stimulated 
OA synovium. The effect on non-stimulated OA synovium can partially be explained 
by the effects seen on polarized macrophages, where BMP-7 increased the CCL18 and 
sCD163 production by M(IL-10), suggesting an anti-inflammatory effect. These data were 
in line with another study134, where it was shown that BMP-7 directed the polarization 
of THP-1 monocytes into an anti-inflammatory state. The anti-inflammatory effect of 
BMP-7 indicate that the modulatory capacity of BMP-7 may depend on the phenotype 
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of the cells that are present in the tissue, assuming that the majority of the macrophages 
in OA synovium have a similar phenotype to IL-10 stimulated primary macrophages. 
On the other hand, the reason for the overall pro-inflammatory effect of BMP-7 seen 
in INFγ+TNFα stimulated synovial tissue remains unclear, although is likely due to a 
decrease of IL1RA expression which led to a reduced M1/M2-index. However no effect 
was seen on pro-inflammatory macrophages in the monolayer cultures. These data 
combined suggest that BMP-7 may also have an effect on other cells than macrophages 
that are present in synovium that are involved in inflammatory processes as well. 
Other studies have shown that intra-articular administration of BMP-7137,149-151 and 
rapamycin152-154 protected OA progression after induction of experimental OA. These 
studies focused mainly on articular cartilage quality in end-stage OA and have not taken 
into account the direct effect of BMP-7 and rapamycin on the synovial membrane. The 
varying effects of these two compounds on IFNγ+TNFα stimulated and non-stimulated 
synovium, underlines the importance of identifying OA stadium in order to clinically 
use BMP-7 or rapamycin as a therapy for OA.
Although statins are known for their pleiotropic effects, pravastatin did not have a 
clear modulatory effect on OA synovial tissue in our study. On polarized macrophages 
however, pravastatin increased sCD163 production in both anti-inflammatory 
phenotypes, which is in line with other studies that have shown anti-inflammatory 
effects of statins on macrophage polarization155,156, chondrocytes157,158, and progression 
of OA and arthritis in vivo159,160. Additionally, systemic statin use has also been shown to 
be associated with reduced progression of knee OA161 and seemed to reduce the activity 
of rheumatoid arthritis in humans162. We chose to assess the effects of pravastatin over 
other statins such as simvastatin, since the latter needs to be bio-activated by the liver, 
or manually if it is not administered orally163. The fact that pravastatin was unable to 
modulate synovial tissue, suggests that it may not be suitable to be used intra-articular 
for guiding synovial inflammation by macrophage phenotype modulation, unless 
specifically targeting M(IL-10) like macrophages.
To conclude, dexamethasone, rapamycin and BMP-7 can modulate the overall 
inflammatory state of OA synovium by altering their expression profile. Future research 
could include large population patient studies to specifically correlate initial synovitis to 
the response after treatment. Directing synovial inflammation to delay the progression 
of OA may therefore be a suitable personalized medicine approach for which the 
optimal compound can be selected when the inflammatory state of the synovium has 
been determined.
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sUPPLeMentary Data
supplementary table s5.1: Primers and probes used for qrt-PCr analysis
gene Primer sequences
IL6
Fw: TCGAGCCCACCGGGAACGAA
Rev: GCAGGGAAGGCAGCAGGCAA
IL1B
Fw: CCCTAAACAGATGAAGTGCTCCTT
Rev: GTAGCTGGATGCCGCCAT
TNFA
Fw: GCCGCATCGCCGTCTCCTAC
Rev: AGCGCTGAGTCGGTCACCCT
CCL18
Fw: GCACCATGGCCCTCTGCTCC
Rev: GGGCACTGGGGGCTGGTTTC
IL1RA
Fw: AACAGAAAGCAGGACAAGCG
Rev: CCTTCGTCAGGCATATTGGT
CD206
Fw: TGGCCGTATGCCGGTCACTGTTA
Rev: ACTTGTGAGGTCACCGCCTTCCT
CD163
Fw: GCGGGAGAGTGGAAGTGAAAG
Rev: GTTACAAATCACAGAGACCGCT
TLR4
Fw: GGCATGCCTGTGCTGAGTT
Rev: CTGCTACAACAGATACTACAAGCACACT
IL10
Fw: CCTGGAGGAGGTGATGCCCCA
Rev: GACAGCGCCGTAGCCTCAGC
TGFB1
Fw: GTGACAGCAGGGATAACACACTG
Rev: CATGAATGGTGGCCAGGTC
Probe: ACATCAACGGGTTCACTACCGGC
GAPDH
Fw: CAACGGATTTGGTCGTATTGGG
Rev: TGCCATGGGTGGAATCATATTGG
Probe: GGCGCCCCAACCAGCC
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abstraCt
Macrophages play a key role in the foreign body response. In this study it was investigated 
whether obesity affects the acute response of macrophages to biomaterials in vitro and 
whether this response is associated with biomarkers in blood. CD14+ monocytes were 
isolated from blood from obese and age and gender matched lean persons. Monocyte 
subsets were determined based on CD14 and CD16 on their surface. C-reactive 
protein (CRP) was measured in peripheral blood. The response of monocyte-derived 
macrophages to polypropylene (PP), polylactic acid (PLA), polyethylene terephthalate 
(PET) monofilament, and PET-multifilament (mPET) in culture was based on cytokine 
production. More IL-6 (for PET), less CCL18 (all materials) and IL-1ra (for PLA) was 
produced by macrophages from obese patients than lean subjects. Body mass index, 
serum CRP and to a lesser extend percentages of monocyte subtypes correlated with IL-6, 
TNFα, CCL18, and IL-1ra production. Taken together, monocyte-derived macrophages 
of obese patients respond more pro-inflammatory and less anti-inflammatory to 
biomaterials than macrophages from lean subjects, depending on the material. These 
results are a step towards personalized medicine for the development of a model or 
even a blood test to decide which biomaterial might be suitable for each patient.
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introDUCtion
Biomaterials are often used in several surgical disciplines such as urology, gynaecology 
and general surgery165. The foreign body response to implanted biomaterials is crucial 
for adapting the material in the human body. Macrophages play a key role in the 
foreign body reaction to biomaterials57. For regenerative biomaterials, an initial pro-
inflammatory (M1) response is necessary for recruiting inflammatory cells to encourage 
the foreign body response, which are necessary events for wound healing including 
ingrowth. However, a prolonged M1 response results in fibrous capsule formation and 
extended inflammation. Therefore, a subsequent transition to the anti-inflammatory 
macrophages (M2), which promotes tissue repair and remodeling, is generally presumed 
to be the preferred modification166. Achieving the desired outcome is individual and 
biomaterial dependent.
In general, obesity seems to be an important factor for adverse outcomes after 
surgery. Observed complications are surgical site infections, impairment of cutaneous 
wound healing, wound failure, anastomotic leakage, and fascia dehiscence167-169. 
These complications are major risk factors to develop incisional hernia or a recurrent 
incisional hernia after repair170,171. Potential factors that increase wound complications 
by obesity include intrinsic tenuous anatomic properties, poor vascularization, 
and cellular and molecular alterations. Inflammatory mediators such as tumor 
necrosis factor alpha (TNFα), interleukin 6 (IL-6), leptin, and angiotensin increase 
simultaneously with increasing mass of adipose tissue and adipocyte size167. These 
factors negatively affect wound healing and are most likely produced by many types of 
cells than macrophages alone. Obesity is also positively correlated with oxidative stress 
which can lead to decreased oxygen tension and impaired fibroblast proliferation and 
collagen synthesis167.
Due to obesity, macrophages undergo a phenotypic switch from M2 to M1, which 
leads to a chronic low-grade systemic inflammation172-176. Monocytes, the precursors 
of macrophages, can be divided into subsets, according to their expression of the 
cell surface antigens CD16 (Fcγ receptor III) and CD14 (a receptor for bacterial 
lipopolysaccharide (LPS))177. The classical monocyte has high CD14 (CD14++) cell 
surface expression and is CD16 negative (CD16−). The non-classical monocyte also 
expresses CD14 at its surface but at an approximately ten times lower level than the 
classical monocyte (CD14+), and is positive for CD16 (CD16++). The intermediate 
monocyte expresses CD14 at a high level (CD14++), and CD16 at an approximately 
ten times lower level than the non-classical monocyte (CD16+). In general, monocytes 
expressing CD16 have a high phagocytic capacity and produce more pro-inflammatory 
cytokines such as TNFα and IL-6, and are therefore considered pro-inflammatory178. 
The classical CD14++/CD16− subset is the predominant population and accounts for 
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approximately 90% in healthy persons. It has been suggested that obesity leads to a 
shift from classical towards intermediate and non-classical monocytes179,180.
Previous in vitro models have shown that culturing macrophages isolated from 
healthy donors on different biomaterials leads to a biomaterial-specific reaction43 and 
that even in a contaminated in vitro model, surgical biomaterials still elicit differential 
reactions in macrophages116. These in vitro models did not take into account patient 
specific characteristics, such as age, smoking, diabetes or obesity. Obesity is a 
growing healthcare issue in the clinics and a subgroup of these patients does receive 
a biomaterial for several reasons like abdominal wall hernia with an increased risk of 
unwanted reactions to the biomaterial or delayed wound healing167,168. Therefore, the 
aims of this study were to investigate how obesity affects the acute host response of 
macrophages to biomaterials in vitro and to examine whether this in vitro response 
can be predicted beforehand by determining monocyte subsets in the blood or by 
measuring the systemic inflammation marker CRP that is a commonly used clinical 
parameter for inflammation.
MateriaLs anD MethoDs
study population
In total we included 20 obese patients and 20 age and gender matched healthy, lean 
(BMI 18-25 kg/m2) volunteers. Obese patients with a BMI >30 kg/m2 were included 
at the department of bariatric surgery at the Maasstad Hospital, Rotterdam. Exclusion 
criteria for both groups were smoking, diabetes mellitus, use of immunosuppressive 
drugs, autoimmune disease or chronic inflammatory disease, and medical history such 
as previous surgery or having a prosthesis (e.g., vascular implants, mesh, osteosynthesis 
material). This study was approved by the Medical Ethical Committee of the Erasmus 
University Medical Center, Rotterdam, Netherlands, in accordance with the Dutch law 
on medical research in humans. Permit number MEC-2014-221, NL47780.078.14. 
Written informed consent was obtained from all patients.
biomaterials
Four types of biomaterials were selected for use in all experiments: polypropylene (PP; 
0.9 g/cm3; Ø 0.10 mm monofilament yarn; ETO (ethylene oxide) sterilized), polyethylene 
terephthalate multifilament (mPET; 1.34 g/cm3; 50 dTex (10−7 kg/m) - 22 filaments 
per yarn (50/22) multifilament yarn; gamma sterilized), polyethylene terephthalate 
monofilament (PET; 1.34 g/cm3; Ø 0.09 mm monofilament yarn; gamma sterilized) 
and polylactic acid (PLA; 1.25 g/cm3; Ø 0.15 mm monofilament yarn; ETO sterilized). 
All materials were provided as yarns braided in the same conformation and with same 
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volumic density. The length of the yarn was adjusted according to the density (g/cm3) 
values of each material (Figure 6.1). The braided materials are created of a mix of 
micro- and macro-porosity that favors cell attachment, particularly for monofilaments, 
and even more particularly, for polypropylene monofilaments.
Monocyte isolation and seeding on biomaterials
Peripheral blood mononuclear cells (PBMC) were isolated from 30 mL blood of obese 
patients and healthy volunteers by gradient density separation using Ficoll-Paque 
PLUS (GE Healthcare Life Sciences, Little Chalfont, UK). The blood from the obese 
patients was obtained preoperatively to bariatric surgery. Monocytes were isolated by 
CD14+ selection. Briefly, the blood was diluted 1:1 with PBS (Gibco; Carlsbad, USA) 
supplemented with 0.1% BSA (Sigma-Aldrich, St. Louis, USA), applied on top of a Ficoll 
layer, and centrifuged at 900 x g for 30 minutes to acquire separation of layers. The 
interphases were collected and washed twice with PBS/0.1% BSA before a 20-minute 
incubation at 4°C with anti-human CD14 MicroBeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Positive selection was performed by Magnetic-acitvated cell 
sorting (MACS). The isolated CD14+ monocytes were kept in suspension in X-VIVOTM 
figure 6.1: experimental flow of our study, including pictures of the yarns and how the yarns 
were placed in the culture wells. The length of the yarns was adjusted according to the density 
of the material. CD14 = cluster of differentiation 14, PP = polypropylene, PLA = polylactic 
acid, PET = monofilament polyethylene terephthalate, and mPET = multifilament polyethylene 
terephthalate.
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15 medium (Lonza, Verviers, Belgium) containing 20% heat inactivated fetal calf serum 
(FCS; Lonza), 50 µg/mL gentamicin (Gibco) and 1.5 µg/mL amphotericin B (Fungizone; 
Gibco), from now on referred to as ‘culture medium’, until seeding. Prior to seeding, 
the biomaterials were pre-conditioned in non-heat inactivated FCS for 2 hours at 37°C 
with agitation. After pre-conditioning, the monocytes were seeded by rotation onto the 
biomaterials for 2 hours at 37°C at 20 rpm (VWR tube rotator, Radnor, Pennsylvania, 
USA). The materials were exposed to 425,000 monocytes per yarn at a concentration 
of 500,000 monocytes/mL. After seeding, the materials were carefully transferred to 
96-well plates (Corning Costar, NY, USA) and cultured in 125 µL culture medium per 
well. Per patient, four different materials in triplicate were cultured. The culture system 
is shown in Figure 6.1. After 2 days of culture, the materials were transferred to new 
wells and medium was refreshed to only take into account the biomaterial adherent 
cells. Twenty-four hours after refreshing, the medium was collected while keeping the 
three samples separate, centrifuged for 10 minutes at 300 x g and stored at -80°C 
for later cytokine quantification. The macrophages adhering to the biomaterials were 
lysed in 125 µL PBS/0.1% Triton-X (Sigma-Aldrich) and stored at -20°C before DNA 
quantification. The remaining CD14+ monocytes that were not used for seeding were 
stored in 20% dimethyl sulfoxide (DMSO)/FCS in liquid nitrogen for flow cytometric 
analysis.
Protein adsorption by the biomaterials
To evaluate potential adsorption of the proteins by the materials, the materials were 
pre-conditioned for 2 hours in non-heat inactivated FCS with agitation, followed by 
2 hours incubation in X-VIVO/20% FCS in a tube rotator at 37°C. Next, the materials 
were transferred to well plates and incubated in X-VIVO/20% FCS for 2 days. After this 
period, the materials were transferred to new well plates and incubated in medium 
containing either 1 ng/mL IL-6 (Peprotech), 250 pg/mL CCL18 (R&D Systems), 1.25 
ng/mL IL-1RA (R&D Systems), 500 pg/mL TNFα or no cytokine. After an additional 
incubation day, the media were harvested, centrifuged at 300 x g and stored at -80°C 
until cytokine quantification. The use dosages were based on the detection ranges of the 
enzyme-linked immunosorbent assays (ELISAs) that were used to determine cytokine 
concentrations.
Cytokine quantification
Enzyme-linked immunosorbent assays (ELISAs) were performed according to 
manufacturer’s instructions to quantify the concentrations of CCL18, IL-1RA, IL-6, and 
TNFα (R&D Systems, Minneapolis, MN, USA) released in the cell culture supernatants. 
These selected cytokines were chosen based on our previous research in which CCL18, 
IL-1RA, IL-6, and TNFα were the most discriminative for the different macrophages 
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phenotypes43,181,182. All measurements fitted within the standard curve, for every 
material and cytokine different dilutions had to be made of the culture medium, ranging 
from a 3 to 100 times dilution. C-Reactive Protein (CRP) levels in the plasma were 
determined using the standard technique at the hospital’s laboratory (Dimension Vista® 
System, Flex reagent cartridge, Siemens Healthcare Diagnostics Products, Germany) 
and expressed in mg/L. CRP is a very common used parameter in all hospitals to detect 
early systemic inflammation, also prior to surgery, especially in obese patients.
Dna quantification
Since cell attachment was different between materials we normalized the protein 
content in the culture media to the amount of DNA on the biomaterial as an indication 
for the cell number. By normalizing for DNA, we adjust for variation in cell number 
allowing to determine the production of cytokines per cell, not influenced by the 
number of cells that adhered to the material. DNA was quantified with a modified 
CYQUANT® cell proliferation assay (Invitrogen, Carlsbad, California, USA), in order 
to normalize the cytokine production for the number of cells. In short, the samples 
were sonicated for 30 minutes at 48 kHz to completely disintegrate the cells. Next, 
a solution containing 250 IU heparin (LEO Pharma, Ballerup, Denmark) and 125 µg 
RNAse (Sigma-Aldrich) were added to the suspensions and incubated for 30 minutes at 
37°C. Finally, 0.375 µL CyQUANT GR dye was added to each sample and fluorescence 
was immediately measured on a SpectraMax Gemini micro plate reader (Molecular 
Devices, Sunnyvale, USA) at 480 nm excitation and 520 nm emission.
flow cytometric analysis
Monocytes were thawed from -180°C and re-suspended at 500,000 cells/mL in 
FACSFlow solution (BD Biosciences) and stained for 30 minutes at 4°C with antibodies 
against human CD14 conjugated with APC-H7 and CD16 conjugated with PE (both BD 
Biosciences), according to the manufacturer’s guidelines. Unstained cells were used as 
negative control. Flow cytometric analysis was performed using the FACSJazz™ (BD 
Biosciences), and data were analyzed using FlowJo (FlowJo v7.6.4/v10; Ashland, OR, 
USA).
statistical analysis
Statistical analysis was performed with SPSS 21.0 (IBM Inc., Chicago, USA). Basic 
characteristics are presented as mean ± standard deviation (SD) and data related to 
cytokines are presented as mean and standard of mean (S.E.M.). An independent 
T-test was used for the age and BMI due to normal distribution of these parameters. 
Mann Whitney U analysis was used for statin use. To compare cytokine levels between 
macrophages obtained from lean and obese subjects and compare cytokine levels 
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between the different materials within the obese and control group, a Kruskal-Wallis 
analysis followed by a post-hoc Mann Whitney U analysis. An M1/M2-index per 
material was calculated based on the cytokine production of pro-inflammatory (M1) 
cytokines IL-6 and TNFα and anti-inflammatory (M2) cytokines CCL18 and IL-1RA. To 
prevent that the calculation is skewed to a certain cytokine that is produced in a higher 
quantity, the production per cytokine is first normalized to the average production of 
that cytokine. The mean of the normalized M1 cytokine levels per patient to the overall 
M1 cytokine levels of all patients, was divided over the mean of the normalized M2 
cytokine levels per patient to the overall M2 cytokine production of all patients, as 
shown in the following formula.
M1 / M2 - index = 
(IL-6per patient + TNFαper patient)
(IL-6all patients + TNFαall patients)
(CCL18per patient + IL1raper patient)
(CCL18all patients + IL1raall patients)
To determine correlations, a non-parametric Spearman test was performed. All reported 
p-values were two-sided; a p-value < 0.05 was considered to indicate statistical 
significance. Since the analyses were exploratory and the groups sizes small, no 
adjustment for multiple testing was performed.
resULts
As a result of our inclusion criteria, BMI was significantly different between the included 
lean and obese subjects. Age, gender and the use of statins were not significantly 
different between the two groups (Table 6.1).
obesity influenced cytokine production by macrophages on biomaterials
The production of IL-6 and TNFα as indicators for a pro-inflammatory response and 
CCL18 and IL-1ra as indicators for an anti-inflammatory response were measured. 
table 6.1: Patient characteristics lean group vs obese patients.
lean (n=20) obese (n=20) p-value
BMI (kg/m2) 22.9 ± 2.6 43.8 ± 6.5 <0.001
gender (male/ female) 2/18 2/18 1.0
age (years) 41.8 ± 13.1 41.3 ± 13.5 0.916
use of statins 0/20 2/20 0.154
Values are means (SD), p-value was estimated by using independent sample T-test
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Macrophages from obese patients produced significantly more IL-6 than macrophages 
from lean subjects when cultured on PET (144.0 pg IL-6/ng DNA vs 102.0 pg IL-6/ng 
DNA, p = 0.022). No significant differences were seen for the other materials regarding 
IL-6 production (Table 6.2 and Supplementary Figure S6.2A). TNFα production was 
not significantly different between the groups for any of the tested materials (Table 
6.2 and Supplementary Figure S6.2B). CCL18 production was significantly higher for 
all materials in the lean group than in the obese group (Table 6.2 and Supplementary 
Figure S6.2C). IL-1ra production was higher in the lean group than in the obese group 
when cultured on PLA (34.6 pg IL-1RA/ng DNA vs 15.5 pg IL-1RA/ng DNA, p = 0.026) 
but not on the other materials (Table 6.2 and Supplementary Figure S6.2D).
No IL-6, TNFα, CCL18, and IL-1RA were detectable in medium with serum alone 
and thus also no difference was seen after incubation of the material in medium with 
serum but without adherent cells. When the proteins of interest were spiked in the 
culture medium, adsorption of these proteins was seen to the materials, with the most 
adsorption of all four proteins to PP, and PLA in the case of IL-6 (Figure 6.2).
table 6.2: the average production of iL-6, tnfα, CCL18, and iL-1ra corrected for Dna by 
macrophages on the different materials.
cytokine material
cytokine production by macrophages (pg protein/ng DNA)
lean
(mean ± SD)
obese
(mean ± SD) p value
IL-6 PP 116.6 ± 97.2 172.4 ± 114.1 0.106
PLA 109.2 ± 67.1 157.4 ± 146.8 0.247
PET 102.0 ± 73.9 144.0 ± 58.4 0.022
mPET 39.2 ± 23.9 68.7 ± 64.0 0.140
TNFα PP 7.9 ± 8.3 5.9 ± 4.9 0.300
PLA 5.0 ± 4.4 3.3 ± 3.1 0.119
PET 3.6 ± 3.8 3.3 ± 1.5 0.417
mPET 1.0 ± 0.9 0.7 ± 0.5 0.421
CCL18 PP 0.8 ± 0.7 0.2 ± 0.3 < 0.001
PLA 1.4 ± 0.9 0.4 ± 0.4 0.002
PET 1.6 ± 1.3 0.5 ± 0.6 0.002
mPET 0.7 ± 0.6 0.3 ± 0.3 0.007
IL-1ra PP 49.4 ± 52.2 24.4 ± 16.8 0.128
PLA 34.6 ± 28.5 15.5 ± 9.0 0.026
PET 32.3 ± 22.6 20.2 ± 13.6 0.071
mPET 18.0 ± 18.4 10.0 ± 12.3 0.057
Bold values denote statistical significance
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The DNA concentration as an indication for the number of attached macrophages 
to the biomaterials, was not significantly different between the lean and obese patients 
in all biomaterials (Supplementary Figure S6.3A). Absolute protein production per 
individual is shown in Supplementary Figure S6.2B-D. When comparing the effect of 
the materials on macrophages within the obese and lean group and per material, PP 
induced higher levels of IL-6, TNFα, and IL-1RA than the other materials, especially 
when compared to mPET. Less clear differences between materials were seen for 
CCL18 production (Figure 6.3).
To compare overall response of the different materials in lean and obese subjects, 
an M1/M2 index was calculated for each condition. The M1/M2 index was significantly 
higher of the obese group than for the lean subjects for PP (p < 0.001), PET (p = 0.001), 
and mPET (p = 0.003) but not for PLA. No differences regarding the M1/M2 index were 
seen between materials for the lean subjects. In obese patients, PLA resulted in the 
lowest M1/M2 index, and mPET the highest (Figure 6.4).
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figure 6.2: Measurements of (a) IL-6, (b) TNFα, (C) CCL18, (D) and IL-1RA in the culture 
medium with and without the incubation of the biomaterials and with and without spiking of 
the protein of interest. White bar indicates measurements in medium with or without incubation 
of the materials. Black bars indicate measurements in medium alone or after incubation with 
the material in the presence of the spiked proteins. Bars represent n= 6 + SD for every bar.U.D.: 
undetectable.
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figure 6.3 Cytokine production corrected for DNA compared per material, in lean subjects or in 
obese subjects. Number of patients per cytokine and per material are indicated in the bars or just 
above the error bar.
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indicate significant differences. A base 2-log scale is used for the Y-axis. PP = polypropylene, PLA 
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polyethylene terephthalate. The number of patients included per material, per group are indicated 
in the bars.
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serum CrP and bMi correlate with cytokine production by macrophages
The average C-reactive protein level in lean subjects was 1.3 ± 1.8 mg/L versus 15.6 ± 
17.1 mg/L in obese patients, p = 0.004 (Supplementary Figure S6.4). CRP concentration 
positively correlated with BMI (Table 6.3). A positive correlation was also seen 
between CRP and IL-6 production in response to the material for all materials, but only 
significant for PP and mPET. A significant negative correlation was seen between serum 
CRP concentration and CCL18 production by macrophages in response to PP, PLA, 
and mPET and between BMI and CCL18 production by macrophages in response to 
PP, PLA, and mPET. CRP also negatively correlated with IL-1RA production in response 
to PP, PLA, and mPET. CRP or BMI did not correlate with TNFα production (Table 6.3).
table 6.3: Correlations between CRP concentration in peripheral blood, BMI of all subjects, and 
cytokine production by the macrophages.
material CRP BMI
r p- value r p-value
CRP - - - 0.64 < 0.001
IL-6 PP 0.37 0.046 0.27 0.111
PLA 0.20 0.310 0.22 0.198
PET 0.40 0.035 0.27 0.146
mPET 0.53 0.003 0.22 0.186
CCL18 PP -0.45 0.012 -0.44 0.006
PLA -0.56 0.002 -0.37 0.028
PET -0.36 0.063 -0.39 0.017
mPET -0.54 0.002 -0.30 0.068
IL-1ra PP -0.36 0.05 -0.15 0.391
PLA -0.45 0.015 -0.20 0.245
PET -0.35 0.075 -0.22 0.211
mPET -0.54 0.013 -0.22 0.267
TNFα PP -0.17 0.382 -0.18 0.295
PLA -0.15 0.438 -0.24 0.16
PET 0.14 0.492  0.02 0.903
mPET -0.17 0.476 -0.30 0.143
Bold values denote statistically significant p-values
table 6.4 Percentages of peripheral blood monocytes subsets in lean (n=9) and obese (n=8) 
subjects. Values are mean +/- SD.
% of monocyte lean obese p-value
classical (CD14++CD16−) 90.9 ± 5.3 77.4 ± 22.0 0.290
intermediate (CD14++CD16+) 2.2 ± 3.4 7.9 ± 13.4 0.336
non-classical (CD14+CD16++) 4.0 ± 3.8 12.9 ± 13.7 0.211
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table 6.5a Spearman correlation between percentages of CD14++CD16− (classical), CD14++CD16+ 
(intermediate), or CD14+CD16++ (non-classical) monocyte subsets and production of cytokines by 
cultured macrophages on the four different materials. The Spearman correlation coefficients (r) 
define the relationship between monocyte subsets from peripheral blood and the production of 
IL-6, CCL18, IL-1ra, and TNFα) by macrophages cultured on PP, PLA, PET, and mPET. Table 6.5b 
shows the correlation between the percentages of monocyte subsets with the M1/M2 index for 
the four different materials. PP = polypropylene, PLA = polylactic acid, PET = monofilament 
polyethylene terephthalate, and mPET = multifilament polyethylene terephthalate.
a material CD14++CD16− CD14++CD16+ CD14+CD16++
r p- value r p-value r p-value
CRP - -0.42 0.120 0.35 0.198 0.35 0.203
BMI -0.16 0.535 0.12 0.636 0.31 0.231
IL-6 PP -0.17 0.541 0.27 0.334 0.26 0.355
PLA -0.43 0.086 0.53 0.028 0.41 0.103
PET -0.54 0.038 0.51 0.052 0.47 0.079
mPET -0.36 0.158 0.38 0.133 0.26 0.323
CCL18 PP 0.28 0.321 -0.13 0.639 -0.23 0.405
PLA 0.16 0.549 -0.32 0.107 -0.18 0.370
PET 0.21 0.451 -0.40 0.045 -0.36 0.073
mPET 0.24 0.353 -0.50 0.007 -0.39 0.039
IL-1ra PP 0.12 0.676 -0.43 0.108 0.18 0.516
PLA 0.16 0.529 -0.29 0.252 0.04 0.889
PET 0.28 0.334 -0.65 0.011 -0.03 0.911
mPET 0.13 0.658 -0.53 0.052 0.16 0.594
TNFα PP -0.37 0.173 0.17 0.550 0.42 0.121
PLA -0.35 0.171 0.37 0.141 0.21 0.428
PET -0.46 0.084 0.30 0.283 0.30 0.296
mPET -0.41 0.167 0.01 0.986 0.42 0.152
b Spearman correlation between percentages of monocyte subsets and M1/M2 index
material
CD14++CD16− CD14++CD16+ CD14+CD16++
r p-value r p-value r p-value
M1/M2 PP -0.59 0.020 0.36 0.182 0.48 0.069
PLA -0.40 0.112 0.37 0.144 0.35 0.174
PET -0.45 0.092 0.26 0.341 0.27 0.328
mPET -0.51 0.038 0.58 0.016 0.41 0.098
Bold values denote statistically significant p-values
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Differences in monocyte subsets between lean and obese patients
Monocytes changed in shape and granularity based on the forward scatter and sideward 
scatter as a result of freezing and thawing (Supplementary Figure S6.1A and S6.1C). 
Percentages of monocytes subsets remained however comparable and not affected 
by freezing and thawing (Supplementary Figure S6.1B and S6.1D). The percentages 
of classical monocytes (CD14++CD16−), intermediate monocytes (CD14++CD16+), or 
non-classical monocytes (CD14+CD16++) in peripheral blood were not statistically 
significantly different between lean and obese subjects (Table 6.4). However, the 
percentages of intermediate monocytes correlated positively with IL-6 for PLA and 
negatively with the CCL18 protein production for PET and mPET, and with IL-1RA for 
mPET. The percentages of non-classical monocytes correlated negatively with CCL18 
production when macrophages were cultured on mPET. No statistically significant 
correlations were seen between percentages of monocyte subsets and TNFα production 
by the macrophages cultured on any of the biomaterials (Table 6.5A). For PP and mPET 
the M1/M2 index significantly correlated with the percentage of classical monocytes. 
Intermediate monocytes significantly correlated negative with the M1/M2 index for 
mPET.
DisCUssion
The use of biomaterials has become common in regenerative medicine. The reaction 
of primary human macrophages to biomaterials has been shown in vitro to be 
biomaterial specific, even when an inflammatory situation is simulated43,116. However, 
the person-dependent foreign body response has not been taken into account in these 
models. In the current explorative study, we investigated the effect of obesity, a growing 
problem in the Western world, on the response of macrophages to biomaterials 
and found that on average macrophages from obese patients respond more pro-
inflammatory to biomaterials as indicated by higher IL-6 and lower CCL18 and IL-1RA 
production than in macrophages from lean persons that were cultured on the same 
materials. In addition, we found that BMI, serum CRP and percentages of monocyte 
subsets in the peripheral blood correlate with the response of the macrophages to the 
biomaterials in vitro, and that these correlations were biomaterial specific. In addition, 
we showed that macrophages derived from monocytes from obese patients still 
respond pro-inflammatory, even when they are not in an obese environment anymore. 
To our knowledge, this is the first study that investigated the differences in macrophage 
response to biomaterials between lean and obese patients.
Obese patients included in this trial had no insulin resistance and therefore, 
according to the WHO criteria, no metabolic syndrome183. Because of the strict 
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inclusion and exclusion criteria, such as no smoking, no implants, and the absence of 
diabetes mellitus we assume that the different responses to the biomaterials between 
lean and obese patients is the result of obesity only and not because of a difference 
in the presence of diabetes or previous operations in which biomaterials were used. 
However, certain risk factors that are unknown at the moment might have influenced 
our measurements and have resulted in the large variation that is sometimes observed 
in the cytokine measurements. Although these patients do not have a metabolic 
syndrome, 50% of them had a CRP level >10 mg/L, indicating systemic low-grade 
inflammation. CRP levels in the serum correlated positively with IL-6 production by the 
macrophages on PP and mPET and negatively with CCL18 and IL-1RA levels on PP, PLA 
and mPET in vitro, showing that CRP has a pro-inflammatory effect on macrophages. 
This was supported by an in vitro study, where it was shown that CRP polarizes human 
macrophages to an M1 phenotype184. A shift from classic monocytes in the peripheral 
blood to intermediate or non-classic monocytes has been seen before as a result of 
obesity174,185,186, of which the latter two subsets are regarded as the pro-inflammatory 
subsets with increasing CD16 positivity174,185,186. We did not observe a statistically 
significant shift when comparing the presence of these subsets between lean persons 
and obese patients. This can be due to the fact that the inclusion criteria were strict 
and only obese patients without a metabolic syndrome were included. In addition, 
the numbers of patients from whom we were able to obtain a sufficient number of 
monocytes to perform additional flow cytometric analysis next to culture with 
biomaterials were low and thus resulting in a low power. Interestingly however, when 
comparing percentages of monocyte subsets in the peripheral blood with the cytokine 
production of monocyte-derived macrophages on biomaterials in vitro, CCL18 and 
IL-1RA production by macrophages on mPET and PET in vitro were correlated with the 
percentages of the different monocyte subsets in the peripheral blood. The percentages 
of classical monocytes correlated positively with CCL18 and IL-1ra levels produced by 
macrophages in culture, the percentages of the more pro-inflammatory intermediate 
and non-classical subsets correlated negatively with CCL18 production in culture. 
CCL18 is a chemokine that is predominantly made by anti-inflammatory macrophages 
43,69, indicating that the initial presence of classical monocytes is associated with the 
differentiation towards anti-inflammatory macrophages. As could be seen from the 
individual levels of IL-6, CCL18 and IL-1RA, not all obese patients had macrophages 
producing high levels of IL-6 and low levels of CCL18 or IL-1RA. No corrections for 
baseline production of the cytokines of interest were made however, because in our 
opinion, this best represents the in vivo situation. Even though no corrections were 
made, differences were still seen between the effects of different biomaterials on cells 
of the same patient. This underlines potential patient specific responses even when 
obesity already changed the metabolic status of the patient and these responses can be 
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explained by serum CRP levels and percentages of monocyte subsets in the blood. The 
production of TNFα in our culture system was not influenced by obesity, this might be 
explained by the short time detection range of TNFα187. Based on our data, it seems that 
PLA followed by PP and PET, are more preferable for obese patients and that all tested 
materials can be more or less equivalently be used for lean for lean patients, assuming 
that a pre-dominant anti-inflammatory reaction is preferred. Although the choice of 
material may be better guided by the inflammatory reaction at the individual patient 
level rather than at the comorbidity category such as obesity. As shown in previous 
clinical studies, no enormous undesirable behavior of multifilament PET mesh (e.g., 
Parietex™ Composite mesh) for hernia repair in obese patients has been reported till 
now, therefore the clinical impact might be moderate188,189. Nevertheless, the patient’s 
outcome can always improve with careful and personalized selection of meshes.
The polymers used in this study are commonly used for materials for soft tissue repair. 
The host-response to materials is not only material dependent but also the porosity, 
topography, and surface of the material influence the biocompatibility166,190-192. The many 
different properties of the material influence the polarization of the macrophages166. In 
the current study, the materials were braided in the same way, but because of different 
diameters of the individual fibers between the materials, the topography was not 
exactly the same. Therefore, the length of the knitted yarn was adjusted to the diameter 
to achieve the best possible comparable material appearance. Interestingly, PET and 
mPET resulted in different M1/M2 indexes, especially when macrophages of obese 
patients were cultured on the materials. This demonstrates that indeed not only the 
polymer but also the architecture of the material is important for elicited responses. 
In this study, PP did not elicit an anti-inflammatory effect based on the cytokines 
measured. This underlines again that not only the polymer itself is important for the 
reaction the material elicits, but also the architecture of the material since in our earlier 
studies we have used meshes instead of yarns43,116,193-195. To optimize the macrophage-
biomaterial contact, necessary for the low numbers of patient cells available for this 
study, braided yarns were chosen in the current study. After spiking of IL-6, TNFα, 
CCL18, and IL-1RA in the culture medium, adsorption was seen, which varied between 
the materials. Since PP had the most adsorption of our proteins of interest, the values for 
PP (and for PLA in the case of IL-6) are most likely an underestimation. However, most 
of the associations and comparisons are made within a biomaterial and a cytokine, not 
comparing two different cytokines or materials with each other. These comparisons and 
associations are therefore unaffected in our opinion by the adsorption of the protein 
of interest. However, the difference in adsorption to each material, and especially the 
high adsorption to PP, might overshadow the differences in reactions elicited by the 
materials.
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After implantation, the biomaterial eventually will be in contact with macrophages, 
but it will also be surrounded by non-adherent macrophages and extracellular matrix. 
We however specifically chose not to include non-adherent macrophages in our 
experimental set-up. The biomaterials were cultured on tissue culture plates made of 
tissue culture polystyrene (TCPS), also a polymer. By transferring the materials with 
their adherent cells to new wells, the medium contained mainly the cytokines from the 
macrophages adhering to the yarns. TCPS most likely will have a totally different effect 
than the extracellular matrix that normally surrounds an implanted biomaterial196,197. 
In fact, we have seen that collagen indeed exerts different effects on macrophages 
than polymers43,116. Therefore, we believed that including cytokine production from 
macrophages adhering to the TCPS would make the system even more artificial, 
especially since the TCPS has a completely different architecture than the used yarns
The proteins IL-6, TNFα, CCL18, and IL-1RA were selected as indicators of pro-
inflammatory and anti-inflammatory responses. We are aware that these cytokines do 
not represent the full spectrum of mediators produced during the foreign body response. 
However previously, we have seen that these mediators are most discriminative between 
pro-inflammatory and anti-inflammatory macrophages43,69. Studies to determine the 
actual in vivo response to the biomaterial and correlating this with the parameters in the 
peripheral blood are necessary to draw firmer conclusions about the predictive value of 
monocyte subset percentages and serum CRP levels for the reaction biomaterials elicit 
in a certain patient.
ConCLUsion
Monocyte-derived macrophages of obese patients respond more pro-inflammatory and 
less anti-inflammatory to biomaterials than macrophages from lean subjects and this 
response depends on the type of biomaterial. This variation in cytokine production 
by the macrophages was associated by the percentages of monocyte subsets in the 
peripheral blood, serum CRP levels, or BMI of the patient. The results of this in vitro study 
offer possibilities and could stimulate future research towards personalized medicine, 
eventually leading to a model that can be used to test biomaterials for tissue repair and 
tissue engineering using patient’s own cells prior to implantation of a biomaterial. In 
addition, our results offer the prospect that monocyte subsets in the blood or serum 
CRP might be measured prior to surgery to predict which biomaterial might be suitable 
for each patient. Studies indeed examining the clinical outcome after implantation of a 
biomaterial in relation to serum CRP, BMI, and monocyte subsets are however needed 
to confirm this.
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sUPPLeMentary Data
supplementary figure s6.1: flow cytometric analysis of fresh (a, b), and frozen monocytes (C, D). 
Forward scatter (FSC) and sideward scatter (SSC) show size and granularity of the cells (a, C) and 
monocyte subsets were determined based on the presence of cluster of differentiation 14 (CD14) 
and CD16 (b, D).
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Male/female-ratio 2/18 2/15 2/18 1/16
Male/female-ratio 2/18 1/17 2/18 1/17
A
supplementary figure s6.2: (a) IL-6, (b) TNFα, (C) CCL18, and (D) IL-1RA production by 
macrophages seeded on different materials corrected for DNA, lean vs. obese groups shown per 
material. Every dot represents a single donor. The line indicates the mean, p-values indicate a 
statistically significant difference. Bars represent the mean, whiskers the SD. Ratios underneath 
the graphs indicate the male/female ratio per measurement and per material. PP = polypropylene, 
PLA = polylactic acid, PET = monofilament polyethylene terephthalate, and mPET = multifilament 
polyethylene terephthalate. Continued on next pages
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B
supplementary figure s6.2 (continued): (a) IL-6, (b) TNFα, (C) CCL18, and (D) IL-1RA production 
by macrophages seeded on different materials corrected for DNA, lean vs. obese groups shown 
per material. Every dot represents a single donor. The line indicates the mean, p-values indicate 
a statistically significant difference. Bars represent the mean, whiskers the SD. Ratios underneath 
the graphs indicate the male/female ratio per measurement and per material. PP = polypropylene, 
PLA = polylactic acid, PET = monofilament polyethylene terephthalate, and mPET = multifilament 
polyethylene terephthalate. 
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C
p<0.001 p=0.002
p=0.002 p=0.007
supplementary figure s6.2 (continued): (a) IL-6, (b) TNFα, (C) CCL18, and (D) IL-1RA production 
by macrophages seeded on different materials corrected for DNA, lean vs. obese groups shown 
per material. Every dot represents a single donor. The line indicates the mean, p-values indicate 
a statistically significant difference. Bars represent the mean, whiskers the SD. Ratios underneath 
the graphs indicate the male/female ratio per measurement and per material. PP = polypropylene, 
PLA = polylactic acid, PET = monofilament polyethylene terephthalate, and mPET = multifilament 
polyethylene terephthalate. 
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D
p=0.026
supplementary figure s6.2 (continued): (a) IL-6, (b) TNFα, (C) CCL18, and (D) IL-1RA production 
by significant seeded on different materials corrected for DNA, lean vs. obese groups shown per 
material. Every dot represents a single donor. The line indicates the mean, p-values indicate a 
statistically significant difference. Bars represent the mean, whiskers the SD. Ratios underneath 
the graphs indicate the male/female ratio per measurement and per material. PP = polypropylene, 
PLA = polylactic acid, PET = monofilament polyethylene terephthalate, and mPET = multifilament 
polyethylene terephthalate. 
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supplementary figure s6.3 (a) The amount of DNA as indication of the number of attached 
macrophages to the biomaterials. DNA is shown as ng/mL for polypropylene (PP), polylactic 
acid (PLA), monofilament polyethylene terephthalate (PET), and multifilament polyethylene 
terephthalate (mPET) for the lean (open bars) and obese (dotted bars) donors. Bars represent 
mean ± S.E.M. n = 20 donors/ group, three samples/ per material/ per donor, p-value indicates a 
significant difference. 
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figure s6.3b, C, D, e Comparing macrophages from lean and obese donors cultured on different 
materials regarding b) IL-6 production and C) TNFα production and D) CCL18 production and 
e) IL-1RA production in ng/ml after 3 days of culture. Every dot represents a single donor. Line 
and whiskers indicate mean ± S.E.M., p-values indicate a statistically significant difference. PP = 
polypropylene, PLA = polylactic acid, PET = monofilament polyethylene terephthalate, and mPET 
= multifilament polyethylene terephthalate. Continued on next pages.
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figure s6.3b, C, D, e (continued) Comparing macrophages from lean and obese donors cultured 
on different materials regarding b) IL-6 production and C) TNFα production and D) CCL18 
production and e) IL-1RA production in ng/ml after 3 days of culture. Every dot represents a single 
donor. Line and whiskers indicate mean ± S.E.M., p-values indicate a statistically significant 
difference. PP = polypropylene, PLA = polylactic acid, PET = monofilament polyethylene 
terephthalate, and mPET = multifilament polyethylene terephthalate. 
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figure s6.3b, C, D, e (continued) Comparing macrophages from lean and obese donors cultured 
on different materials regarding b) IL-6 production and C) TNFα production and D) CCL18 
production and e) IL-1RA production in ng/ml after 3 days of culture. Every dot represents a single 
donor. Line and whiskers indicate mean ± S.E.M., p-values indicate a statistically significant 
difference. PP = polypropylene, PLA = polylactic acid, PET = monofilament polyethylene 
terephthalate, and mPET = multifilament polyethylene terephthalate. 
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supplementary figure s6.4: C-reactive protein (CRP) levels in mg/L in plasma of lean subjects 
vs. obese patients. The middle line in box represent the median and whiskers the minimum and 
maximum; lean (0-7 mg/L) and obese (0-75 mg/L).
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abstraCt
After implantation of a biomaterial, an inflammatory response involving macrophages 
is induced. The behavior of macrophages depends on their phenotype and by directing 
macrophage polarization, unwanted effects may be avoided. In this study, the 
possibility to modulate the behavior of macrophages activated by biomaterials, was 
assessed in an in vitro model. Primary human monocytes were seeded on polyethylene 
terephthalate, polypropylene and polylactic acid yarns, and treated with medications 
frequently used by patients: rapamycin, dexamethasone, celecoxib or pravastatin. 
Modulation of the adhering macrophages with rapamycin resulted in a generally pro-
inflammatory effect. Dexamethasone caused an overall anti-inflammatory effect on the 
macrophages cultured on either material, while celecoxib only affected macrophages 
adhering to polyethylene terephthalate and polylactic acid. Pravastatin increased pro-
inflammatory genes of macrophages cultured on polypropylene and polylactic acid. 
Pairwise comparison revealed that macrophages adhering to polylactic acid seemed to 
be more susceptible to phenotype modulation than when adhering to polypropylene 
or polyethylene terephthalate. This data shows that macrophages activated by the 
biomaterials can be modulated, yet the degree of the modulatory capacity depends 
on the type of material. Combined, this model provides insights into the possibility of 
using a medication in combination with a biomaterial to direct macrophage behavior 
and thereby possibly avoiding unwanted effects after implantation.
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introDUCtion
Biomaterials are commonly used in orthopedics, gynecology, cardiology, reconstructive 
surgery and general surgery. After implantation, the host immune system will interact 
with materials by blood-material interaction, matrix formation, acute inflammation, 
chronic inflammation, granulated tissue development, and a foreign body reaction 
that is eventually followed by fibrosis57. Adverse effects due to implantation include 
material-induced inflammation, excessive fibrosis, excessive coagulation and 
infection58. Macrophages are members of the mononuclear phagocyte system that 
include tissue macrophages, circulating monocytes and precursor monocytes in 
the bone marrow198. They are pivotal in the initial response following biomaterial 
implantation. Macrophages can adhere to the material and become activated and 
acquire a phenotype ranging from pro-inflammatory to anti-inflammatory47. In vitro, 
pro-inflammatory (M1 or classically activated) macrophages develop when monocytes 
are simultaneously subjected to interferon-γ (IFN-γ) and lipopolysaccharide (LPS) or 
tumor necrosis factor alpha (TNFα)45. Anti-inflammatory (M2 or alternatively activated) 
macrophages can be further divided into subtypes depending on the stimuli. One of 
the subtypes develops when exposed to IL-4 or IL-13, also referred to as ‘M2a’, and the 
‘M2c’ subtype develops when stimulated with IL-1038,59.
In the field of orthopedics, polyethylene is the most commonly used polymer for 
metal-on-plastic prosthesis for total hip arthroplasty in the United States199. Although 
improvements of these polymers (e.g., ultra-high-molecular-weight polyethylene 
(UHMWPE)) have increased durability, wear debris accumulates in the joint space 
and interact with the resident tissue cells. Macrophages are key players that become 
activated and initiate immune responses due to exposure to wear debris200,201. They have 
been shown to play an important role in particle wear-induced synovitis, osteolysis202,203 
and aseptic loosening of hip prostheses204,205, which are major causes of failure of total 
hip replacements and account for 30-75% of all revision surgeries206-209. In other fields, 
macrophages are in many cases the underlying initiators or driving forces that control 
the progression of numerous inflammation mediated diseases25,210,211. Studies have 
shown in vitro that monocyte/macrophages can adhere to biomaterials in vitro, become 
activated, and secrete proteins in a pro-inflammatory or anti-inflammatory manner, as 
reviewed by Boersema, et al.193. Previously, we have shown that the behavior of different 
macrophage phenotypes can be modulated using compounds68. These compounds are 
members of commonly used medication groups that are in literature described to have 
effects on inflammatory cells or inflammation in general129-131,135,136,138,143,148,212,213. Since 
these medications were able to modulate different macrophage phenotypes, and their 
effect was dependent on the phenotype, we hypothesized that these medications can 
also modulate the phenotype of macrophages activated by biomaterials. The possibility 
Chapter 7
124
to modulate adhering macrophages can eventually be used to influence the foreign 
body reaction after implantation of a biomaterial. Therefore, the aim of this study was 
to investigate in vitro as a proof of concept whether the behavior of human monocyte-
derived macrophages activated by a biomaterial can be modulated by rapamycin, 
dexamethasone, celecoxib or pravastatin, to direct macrophage polarization. To assess 
this, human monocyte-derived macrophages were seeded on three commonly used 
biomaterials: polypropylene, polyethylene terephthalate and polylactic acid followed 
by treatment of the medications. Gene expression analysis and protein production were 
used as parameters to assess the effects of the medications on the macrophages.
MateriaLs anD MethoDs
Monocyte isolation and seeding on biomaterials
Monocytes were isolated from 13 buffy coats (male donors, 52±14 years) purchased 
from the national blood bank (Sanquin Blood bank, Amsterdam, the Netherlands). 
CD14+ monocytes were acquired from the buffy coats by density gradient separation 
using Ficoll Paque Plus (GE Healthcare Life Sciences, Chicago, USA) followed by 
magnetic activated cell sorting (MACS) using human CD14 microbeads (Miltenyi 
Biotec, Bergisch Gladbach, Germany) as described previously43. Prior to seeding, the 
biomaterials were pre-conditioned with 100% non-heat-inactivated fetal calf serum 
(FCS; Lonza, Verviers, Belgium) for 2h at 37°C to improve attachment conditions for the 
monocytes due to the presence of complement. For each experiment, the monocytes 
were pooled from at least two donors. The monocytes were seeded for 2h at 37°C by 
rotation at 20 rpm (VWR, Pennsylvania, USA) on monofilament polypropylene (ρ=0.9 
g/cm3; ø=0.10 mm; l=8 cm), polyethylene terephthalate (ρ=1.34 g/cm3; ø=0.09 mm; 
l=8.8 cm,) or polylactic acid (ρ=1.25 g/cm3; ø=0.10 mm; l=8 cm) yarns (Medtronic-
Sofradim, Trévoux, France). The length of the yarns was adjusted for the density and 
volume of the materials. Each yarn was exposed to 850,000 CD14+ monocytes in a 
cell suspension of 500,000 monocytes/mL. The materials with adhering monocytes 
were cultured for 3d in 48 well-plates in 250 µL culture medium (X-VIVO-15 (Lonza, 
Verviers, Belgium) supplemented with 20% heat-inactivated FCS, 50 µg/mL gentamicin 
(Gibco, Carlsbad, USA) and 1.5 µg/mL amphotericin B (Fungizone; Gibco)) at 37°C and 
5% CO2 to allow differentiation into activated macrophages. A concentration of 20% 
FCS was chosen based on pilot experiments and previous studies, where this culture 
condition was more favorable in terms of macrophage viability and differentiation 
capacity into different phenotypes in vitro5,60,68,69.
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Modulation of macrophages adhering to biomaterials
After 3d of differentiation in response to the biomaterial, the medium was removed and 
replaced with medium containing 1 or 10 ng/mL rapamycin (R&D Systems), or 10−8 or 
10−7 M dexamethasone (Sigma-Aldrich), or 0.5 or 5 µM pravastatin (Sigma-Aldrich), 
or 0.1 or 1 µM celecoxib (Sigma-Aldrich). Concentrations were chosen based on 
literature136,138-140 and previous work where macrophages cultured in monolayers 
were treated with these medications68. Dimethyl sulfoxide (DMSO) was used as 
a vehicle for dexamethasone and rapamycin and the final DMSO concentration in 
the cultures was <0.01%. To only take into account the adhering macrophages to the 
biomaterials, the materials were transferred to new well plates after 2d of culture and 
the medium containing medications was refreshed. After an additional 24 hours, the 
medium was harvested, centrifuged at 300 x g, aliquoted and stored at -80ºC until 
protein measurement. The yarns were either stored in PBS/0.1% Triton X-100 (Sigma-
Aldrich) at -20ºC for measuring the number of adhering cells or in TRIzol Reagent 
(Invitrogen, Carlsbad, USA) at -80ºC until processing for gene expression analysis. The 
timeline for this experiment is based on pilot studies and our previous work 43,60,68 
where we have seen that after 3d of culture and 3d modulation, macrophages cultured 
in monolayers can polarize and be modulated towards specific phenotypes, and 
present a distinct gene expression and protein profile. Per material, all experiments 
were conducted independently three times (n=3 in triplicate) with pooled monocytes 
from at least two buffy coats per experiment.
Quantification of iL-6, CCL18 and sCD163 protein production by 
macrophages cultured on biomaterials
The concentrations of proteins released in the cell culture supernatants were quantified 
using enzyme-linked immunosorbent assays (ELISAs). Interleukin 6 (human IL-6 ELISA 
development kit; PeproTech), Chemokine (C-C motif) ligand 18 (human CCL18 DuoSet 
ELISA; R&D Systems) and soluble cluster of differentiation 163 (Human sCD163 DuoSet 
ELISA; R&D Systems) were measured according to the manufacturer’s instructions. These 
proteins were chosen based on previous studies43,60,68 as they are able to indicate the 
phenotype of the cultured macrophages. For technical reasons, medium was diluted at 
least 1:1. To normalize the cytokine production for the number of macrophages adhering 
to the biomaterials, the cell numbers were determined in the cell suspensions in which 
the materials were collected. For the standard, CD14+ cells were cultured in monolayers 
in X-VIVO/20% heat-inactivated FCS in Nunc UpCell thermo reversible culture plates 
(Thermo Fisher Scientific). The cells were non-enzymatically detached from the plates 
by reducing the temperature to 32°C and the macrophages were collected in PBS/0.1% 
Triton X-100 to be used as a standard. CyQUANT GR dye (Invitrogen, Carlsbad, USA) 
was added to the cell suspensions according to the manufacturer’s instructions and 
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the fluorescence was measured at 480 nm excitation and 520 nm emission with a 
Spectramax Gemini (Molecular Devices, Sunnyvale, USA).
gene expression analysis of adhering macrophages
The mRNA of the macrophages attached to the yarns was isolated using TRIzol 
Reagent according to manufacturer’s instructions. Quantification of total extracted 
mRNA was determined using a NanoDrop ND-8000 spectrophotometer (Thermo 
Fisher Scientific Inc., Waltham, USA) at 260/280 nm. Complementary DNA (cDNA) 
was synthesized using the RevertAid First Strand cDNA Synthesis Kit (Thermo 
Fisher Scientific, Waltham, USA) according to manufacturer’s instructions. Finally, 
PCR analysis was conducted with a Bio-Rad CFX96 Real-Time PCR Detection 
System using TaqMan® Universal PCR Master Mix (Applied Biosystems, Carlsbad, 
USA) or qPCRTM Mastermix Plus for SYBGR® Green I (Eurogentec, Liege, Belgium). 
Expression of Interleukin-1B (IL1B; Fw: CCCTAAACAGATGAAGTGCTCCTT; 
Rev: GTAGCTGGATGCCGCCAT), IL6 (Fw: TCGAGCCCACCGGGAACGAA; 
Rev: GCAGGGAAGGCAGCAGGCAA), Tumour necrosis factor-α (TNFA; Fw: 
GCCGCATCGCCGTCTCCTAC; Rev: AGCGCTGAGTCGGTCACCCT), chemokine 
(C-C motif) ligand 18 (CCL18; Fw: GCACCATGGCCCTCTGCTCC; Rev: 
GGGCACTGGGGGCTGGTTTC), Mannose receptor, C type 1/CD206 (MRC1/CD206; 
Fw: TGGCCGTATGCCGGTCACTGTTA; Rev: ACTTGTGAGGTCACCGCCTTCCT) 
and cluster of differentiation 163 (CD163; Fw: GTTGGCCATTTTCGTCGCATT; 
Rev: CTCTCCTCTTGAGGAAACTGCAA) were assessed, as they can be used to 
discriminate between different macrophage phenotypes 43,45,68. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; Fw: CAACGGATTTGGTCGTATTGGG; Rev: 
TGCCATGGGTGGAATCATATTGG; Probe: GGCGCCCCAACCAGCC), Beta-actin 
(ACTB; Fw: CCTGGCACCCAGCACAAT; Rev: GGACAGCGAGGCCAGGAT), 
Beta-2-microglobulin (B2M; Fw: TGCTCGCGCTACTCTCTCTTT; Rev: 
TCTGCTGGATGACGTGAGTAAAC) and hypoxanthine phosphoribosyltransferase 1 
(HPRT1; Fw: TATGGACAGGACTGAACGTCTTG; Rev: CACACAGAGGGCTACAATGTG; 
Probe: AGATGTGATGAAGGAGATGGGAGGCCA) were all tested as housekeepers 
for primary human monocyte-derived macrophages. GAPDH was found to be the 
most stable using geNorm software (Biogazelle NV, Zwijnaarde, Belgium)214 (data not 
shown) and was further used as normalization of the genes of interest. The amplification 
efficiency of all primers was between 0.9 and 1.1 and the relative expression was 
determined by the 2−ΔCT formula.
statistics
MS Excel 2013 and PASW Statistics 22.0 (SPSS Inc. Chicago, USA) were used for 
statistical analysis. To take into account donor variations, a mixed linear model 
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without log-transformation was used followed by a Bonferroni’s post hoc comparisons 
test to compare gene expression and protein levels between a compound treatment 
and the untreated control. Medication treatment of macrophages per material (e.g., 
macrophages cultured on polypropylene treated with rapamycin) were defined as 
fixed factors in the model, and the individual experiments were considered as random 
factors, using n=9 per condition in the model. For calculation purposes, when protein 
levels were undetectable in the assay, samples were assigned the detection limit of the 
ELISA assay as provided by the manufacturer (IL-6: < 23.44 pg/mL; CCL18: <7.8 pg/
mL and sCD163: <156 pg/mL) and corrected for the lowest used dilution factor in the 
assay. Initial differences between materials (i.e., number of adhering cells and protein 
production) were evaluated using one-way ANOVA after log-transformation, followed 
by a Bonferroni’s post hoc test. To assess which material favored phenotype modulation, 
the protein levels were normalized to untreated controls, log-transformed, and pair 
wised compared using one-way ANOVA followed by a Bonferroni’s post hoc test to 
correct for multiple comparisons. Differences were considered statistically significant 
for p<0.05. All data displayed in the graphs are non-log-transformed data points.
resULts
iL-6 and CCL18 are secreted by adherent macrophages in response to 
biomaterials
The number of macrophages that adhered to the biomaterials differed between materials. 
Without modulation, more macrophages adhered to polyethylene terephthalate (58584 ± 
19951 cells) than to polypropylene (26312 ± 10781 cells), but not more than polylactic 
acid (36648 ± 13958 cells) (Supplementary Figure S7.1A). Based on our previous 
studies, IL-6 protein production can be considered as a marker for pro-inflammatory 
M1/M(IFNγ+TNFα) macrophages in this culture system, CCL18 as marker for tissue 
repair M2a/M(IL-4), and sCD163 protein production as marker for anti-inflammatory 
M2c/M(IL-10)43,60,68. Without modulation by the medications, IL-6 and CCL18 were 
produced by the macrophages adhering to polyethylene terephthalate, polypropylene, and 
polylactic acid. IL-6 protein levels of macrophages adhering to polyethylene terephthalate 
were slightly lower than of macrophages adhering to polypropylene. sCD163 was, with 
the exception of one polylactic acid sample, not detected in the medium of macrophages 
adhering to any of the materials (Supplementary Figure 7.1B).
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figure 7.1: Modulation of macrophages adhering to polypropylene. (a) Gene expression 
levels and (b) protein levels of macrophages adhering to polypropylene after modulation with 
rapamycin, dexamethasone, celecoxib and pravastatin. Vehicle treated conditions are indicated 
by grey symbols, where 0.01% DMSO was used as vehicle for rapamycin, dexamethasone and 
celecoxib, and X-VIVO medium was used as vehicle control for pravastatin. Statistical evaluation 
was conducted with a linear mixed model followed by a Bonferroni’s post hoc test. No statistical 
analysis was conducted for sCD163 since the protein was not detectable in the untreated control 
conditions. The data is presented as dot plots including the grand means for n=3 independent 
experiments with three samples per experimental condition. Abbreviations: IL6: Interleukin 6, 
IL1B: Interleukin 1β; TNFA: Tumor Necrosis Factor-α; CCL18: C-C motif chemokine ligand 18; 
CD206: cluster of differentiation 206; CD163: cluster of differentiation 163.
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gene expression and protein secretion profiles of biomaterial-adhering 
macrophages can be modulated with commonly used medications
In pilot studies, concentrations of 1, 10 and 100 ng/mL rapamycin, 10−8M, 10−7M, and 
10−6M dexamethasone, and 0.5, 5, and 50 µM pravastatin were cultured on macrophages 
in monolayers. As the highest concentrations did not affect the macrophages differently 
than the lowest two in these monolayer cultures (data not shown), only the two lowest 
were used for the current experiments to modulate macrophages adhering to biomaterials. 
Since then the concentrations of 10 ng/mL rapamycin, 10−7 M dexamethasone, 5 µM 
pravastatin and 1 µM celecoxib exerted extremely minor differences compared to a ten 
times lower concentration (Supplementary figure S7.2), only the lowest concentrations 
of the medications were further used in this study.
To assess whether the modulation by the medications initiated processes 
related to macrophage phenotype polarization, expression of genes encoding 
for pro-inflammatory proteins (IL6, IL1B and TNFA) and genes encoding for 
anti-inflammatory proteins (CCL18, CD206 and CD163) were measured. Rapamycin, 
dexamethasone and pravastatin were all able to alter the gene expression profiles of 
macrophages adhering to polypropylene. This was indicated by increased expression 
levels of TNFA and CD206 after treatment with rapamycin compared to the expression 
levels of macrophages adhering to polypropylene without treatment. Dexamethasone 
lowered TNFA expression, and increased CCL18, CD206, and CD163 expression, 
whereas pravastatin lowered IL6 and IL1B compared to the untreated macrophages 
adhering to polypropylene (Figure 7.1A. On protein level, IL-6 remained unchanged 
in response to any of the medication treatments. CCL18 production of macrophages 
adhering to polypropylene was significantly higher when treated with dexamethasone 
and pravastatin than of the untreated macrophages. sCD163 was undetectable, except 
after treatment with dexamethasone (Figure 7.1B).
Of the macrophages adhering to polyethylene terephthalate, treatment with 
rapamycin caused higher expression of IL1B and CD206 than in the untreated controls 
and lower expression of CCL18. Dexamethasone lowered TNFA while CCL18, CD206 
and CD163 expression was higher than the expression of the untreated controls. 
Celecoxib increased CD163 expression (Figure 7.2A). IL-6 protein production was not 
significantly affected by any of the treatments. CCL18 production was reduced after 
treatment with rapamycin, while dexamethasone caused higher CCL18 production 
than in the untreated controls. sCD163 was only detectable when the macrophages 
were treated with dexamethasone (Figure 7.2B).
On gene expression level of macrophages adhering to polylactic acid, rapamycin 
treatment resulted in lower expression levels of IL6, CCL18 and CD163, while TNFA 
and CD206 expression levels were higher. Dexamethasone reduced IL6, TNFA, and 
simultaneously increased CCL18, CD206, and CD163. Expression of CD206 was higher 
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figure 7.2: Modulation of macrophages adhering to polyethylene terephthalate. (a) Gene 
expression levels and (b) protein levels of macrophages adhering to polypropylene after 
modulation with rapamycin, dexamethasone, celecoxib and pravastatin. Vehicle treated 
conditions are indicated by grey symbols, where 0.01% DMSO was used as vehicle for rapamycin, 
dexamethasone and celecoxib, and X-VIVO medium was used as vehicle control for pravastatin. 
Statistical evaluation was conducted with a linear mixed model followed by a Bonferroni’s post 
hoc test. No statistical analysis was conducted for sCD163 since the protein was not detectable 
in the untreated control conditions. The data is presented as dot plots including the grand means 
for n=3 independent experiments with three samples per experimental condition.
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after the macrophages were treated with celecoxib and expression of IL1B was higher 
after treatment with pravastatin (Figure 7.3A). On protein level, none of the medications 
affected IL-6 or CCL18 production of the macrophages adhering to polylactic acid, 
while sCD163 was undetectable in the majority of the control samples, though it was 
detectable after the adhering macrophages were treated with dexamethasone (Figure 
7.3B).
Polylactic acid-activated macrophages seem more susceptible to 
phenotype modulation than macrophages adhering to polypropylene or 
polyethylene terephthalate
To compare the biomaterial-dependent modulation of the macrophages, gene 
expression levels of IL6, IL1B, TNFA, CCL18, CD206 and CD163, and protein 
production of IL-6, CCL18 and sCD163 were normalized to the untreated controls 
and pairwise compared between materials. On gene expression level, the relative 
change in IL6 expression levels of macrophages adhering to polylactic in response 
to dexamethasone, was lower than when the macrophages were adhering to 
polyethylene terephthalate, while the change in IL1B in response to pravastatin 
was higher in polylactic acid-adhering macrophages than when adhering to 
polypropylene (Supplementary Table S7.1). The relative change in CD206 expression 
in response to rapamycin was higher when macrophages adhered to polylactic 
acid than to polyethylene terephthalate (Supplementary Table S7.2). The relative 
change in expression of CCL18 of macrophages that adhered to polypropylene and 
were modulated with rapamycin, was higher than when macrophages adhered to 
polyethylene terephthalate or polylactic acid. The change in expression of CD206 in 
response to pravastatin was higher of macrophages adhering to polypropylene than 
when adhering to polyethylene terephthalate (Supplementary Table S7.2). The change 
in IL-6 protein production by macrophages as a result of celecoxib and pravastatin 
treatment, was significantly higher when adhering to polyethylene terephthalate than 
when adhering to polypropylene or polylactic acid. The relative change in sCD163 
after modulation with dexamethasone was lower when macrophages were adhering 
to polypropylene than when the macrophages were adhering to polyethylene 
terephthalate or polylactic acid. The relative change in CCL18 protein production 
as a result of the modulation, was only higher when macrophages were cultured on 
polyethylene terephthalate than when cultured on polylactic acid (Table 7.1).
Chapter 7
132
A
B
IL6

" 





%


$
"
!



$

" 




 
#!
""

 

 	
 
 
 



"
#
"





	




"

	
!





!








 


 
 




 




IL1B TNFA
CCL18 CD206 CD163


	




"

	
!





!








 


 
 




 






	




"

	
!





!








 


 
 





 






	




"

	
!





!








 


 
 




 





" 





%


$
"
!



$

" 




 
#!
""

 

 	
 
 
 




"
#
"



p=.022
p=.039
p=.011
p<.001
p<.001
p<.001
p=.006
p=.001
p<.001
p<.001 p<.001
p=.035
p=.015
IL-6
! 
%#!



"

(
 

'
%
$!
 

!
'
! 
%#!




#
&$
%%
 
 
 


	
"
"#
!%
 
"




$#
(&$
!


%
"
+ 
#

*"
(
'$
#
!
$
* 
$#
(&$
!



&
)'
(( 
#
 
 

 	
 
 



%
%&
$(
 #
%



CCL18
! 
%#!



"

(
 

'
%
$!
 

!
'
! 
%#!




#
&$
%%
 
 	
 
 

$


	
"
"#
!%
 
"



sCD163
Polylactic acid




 


 
#!
""

#
&$
%%
 



TNFA
CD163


!








 




$

" 




 
#!
""

<.001
<.001
p=.035

!
'
! 
%#!




#
&$
%%
 

sCD163



TNFA
CD163


	




"

	
!





!








 


 
 




 





" 





%


$
"
!



$

" 




 
#!
""

 

 	
 
 
 




"
#
"



p<.001
p<.001
p<.001
p<.001
p=.035
"

(
 

'
%
$!
 

!
'
! 
%#!




#
&$
%%
 
 	
 
 

"
"#
!%
 
"



sCD163



figure 7.3: Modulation of macrophages adhering to polylactic acid. (a) Gene expression 
levels and (b) protein levels of macrophages adhering to polypropylene after modulation with 
rapamycin, dexamethasone, celecoxib and pravastatin. Vehicle treated conditions are indicated 
by grey symbols, where 0.01% DMSO was used as vehicle for rapamycin, dexamethasone and 
celecoxib, and X-VIVO medium was used as vehicle control for pravastatin. Statistical evaluation 
was conducted with a linear mixed model followed by a Bonferroni’s post hoc test. No statistical 
analysis was conducted for sCD163 since the protein was not detectable in the majority of the 
samples of the untreated control conditions. The data is presented as dot plots including the grand 
means for n=3 independent experiments with three samples per experimental condition.
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DisCUssion
In this study we have shown as proof of concept that the gene expression and protein 
production profile of macrophages activated by the biomaterials polypropylene, 
polyethylene terephthalate and polylactic acid, can be modulated in vitro by medications 
that are commonly used by patients. This modulation capacity seems to depend on the 
type of biomaterial that is responsible for the initial activation of the macrophages. This 
knowledge may be applied by the possibility to utilize commonly used medications in 
combination with a biomaterial to direct macrophage behavior and thereby avoiding 
unwanted effects after implantation.
In our in vitro model, three types of biomaterials were investigated that represent 
frequently used materials. To limit the parameters that may influence macrophage 
polarization and to be able to study the effect of the material property, the biomaterials 
were all braided into a yarn in the same manner. However, due to differences in diameter 
of the individual fibers, the topography between the materials was not identical. In this 
study, and as well as our previous work215, we found very minimal differences between 
materials regarding initial activation of the macrophages, which is in contradiction with 
conducted studies by others as reviewed elsewhere193. This discrepancy does indicate 
the importance of not only material composition and property, but architecture as 
well on macrophage polarization. Interestingly, even though the three materials did 
not cause differences in initial secretion levels of IL-6, CCL18, and sCD163, and very 
minimal differences in IL-6 levels prior to modulation, the modulatory response of the 
macrophages were biomaterial dependent.
Treating the adhering macrophages with rapamycin, an immunosuppressive drug, 
caused a generally pro-inflammatory effect, due to suppression of genes encoding 
for anti-inflammatory proteins and simultaneously enhancing genes encoding for 
pro-inflammatory proteins. The stimulating effect of rapamycin on pro-inflammatory 
macrophages might suggest its use for controlling severe fibrotic reactions. On the other 
hand, treating the macrophages adhering to any of the materials with dexamethasone, a 
corticosteroid, always resulted in increased expression levels of anti-inflammatory genes, 
while levels for pro-inflammatory genes remained unaffected or were slightly lower. This 
shows that dexamethasone specifically enhances the performance of anti-inflammatory 
macrophages, rather than suppressing pro-inflammatory macrophages. On protein 
level, the effect of dexamethasone was clearly seen by the fact that only dexamethasone 
treatment caused detectable levels of sCD163 produced by the macrophages cultured 
on either material, and CCL18 was additionally higher when the macrophages were 
cultured on polyethylene terephthalate. This is a striking finding, as chronic systemic 
steroid use may complicate wound healing216, likely due to inhibition of specific factors 
secreted by dermal fibroblasts such as keratinocyte growth factor217. The fact that in 
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our previous study68, the function of tissue repair macrophages (i.e., M(IL-4) and M(IL-
10)) were significantly enhanced in vitro, indicates a specific advantageous action of 
dexamethasone on macrophages. In-depth research of its use for controlling severe 
inflammatory reactions after biomaterial implantation may be of clinical importance. 
Both the overall pro-inflammatory effect of rapamycin and the anti-inflammatory effect 
of dexamethasone on the adhering macrophages, were expected and in concordance 
with our previous work where we modulated macrophages of specific subtypes in 
conventional monolayer cultures68 and generally emphasizes the use of glucocorticoids 
for macrophage polarization47,73. Celecoxib, a selective COX-2 inhibitor, did not clearly 
affect the expression levels of the genes of interest of the macrophages that were cultured 
on any of the selected materials. On protein level, celecoxib did not significantly affect 
IL-6, CCL18 or sCD163 production of the macrophages adhering to any of the materials. 
Though when comparing the relative protein production to that of the untreated controls, 
celecoxib treated macrophages adhering to polyethylene terephthalate produced more 
IL-6 than when adhering to polyethylene terephthalate or polylactic acid, suggesting that 
the protein secretion and the modulatory potential of celecoxib is dependent on the 
type of biomaterials that activated the macrophages initially. Pravastatin, a cholesterol 
synthesis inhibitor used by patients at risk of cardiovascular disease, lowered expression 
levels of pro-inflammatory genes of macrophages cultured on polypropylene, but did not 
affect any of the genes of interest of macrophages cultured on polyethylene terephthalate 
and polylactic acid. Protein levels of CCL18 of the macrophages increased in response 
to pravastatin when cultured on polypropylene, and had the tendency to increase when 
cultured on polyethylene terephthalate, suggesting an overall anti-inflammatory effect 
of pravastatin. This effect was partially expected, since statins have been shown to exert 
many pleiotropic effects, among which anti-inflammatory effects155,156,218. Atorvastatin 
reduced expression of CXCR7, a chemokine receptor involved in macrophage migration, 
in the human THP-1 cell line156 and induced expression of CD206, IL10 and CCL18 in 
human monocyte derived macrophages155. Striking though, is that in our previous study68, 
pravastatin only affected protein secretion levels of sCD163 when macrophages were 
cultured in a monolayer, while in the current study, CCL18 protein levels were increased 
after treatment. This again confirms that the type of biomaterial determines the protein 
secretion profile and thus the capacity to modulate this profile.
After pairwise comparison of both the gene expression and protein production 
relative to the controls per material, we could not determine a very clear conclusion 
that one of the three tested biomaterials was more sensitive to allow phenotype 
modulation of adhering macrophages. Yet, macrophages adhering to polylactic acid 
appeared to have the tendency to be more susceptible to phenotype modulation, as the 
relative change in gene expression levels and protein levels of the genes and proteins 
of interest, were more often affected, in either direction, by the medications when 
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the macrophages where adhering to polylactic acid then when they were adhering to 
polypropylene or polyethylene terephthalate. In some cases, gene expression levels 
and protein levels do not correspond with each other, likely due to post-translational 
processing of the proteins. By measuring the gene expression levels, we acquire an 
indication of an array of proteins that may be produced, but it remains an indication219,220 
and should therefore be carefully interpreted. Furthermore, when we treated the 
adhering macrophages with a ten times higher concentration of the medications, only 
minor differences between concentrations were found. This could either be due to 
non-specific actions of the medications, or on the other hand, emphasize the sensitivity 
of macrophages to become activated after exposure to a minimal stimulus.
Today, understanding modulation of macrophage polarization in response to biomaterials 
has become of increased interest, since macrophages significantly contribute to the response 
of the host to the material. Various ingenious methods to alter macrophage polarization from 
an engineering point of view have been proposed, such as altering surface properties of the 
material itself221. These methods may seem promising but require alterations of the material 
itself which may result in different outcome and advantageous properties of the material 
may have to be sacrificed. The possibility to modulate biomaterial-adhering macrophages 
using medications, as we have shown in the current study, opens up potential applications 
to direct adverse effects after implantation of a material. Modulating the phenotype of these 
macrophages can be conducted by combining the medication with a biomaterial that acts 
as a controlled release system for local macrophage modulation222,223 as systemic use of 
the medication could have a general impact on wound healing. Moreover, in terms of 
clinical application, the results of this study suggest that differences in the responses of 
macrophages can be expected by patients who are chronically using medications that 
belong to the medication groups that were evaluated in this study. This knowledge could 
eventually contribute to the choice of drug prescriptions when biomaterials are involved, 
and thus might provide a small step towards future personalized medicine. In vivo 
experiments should be conducted to determine whether macrophage modulation would 
affect the foreign body response after implantation and favors wound healing.
ConCLUsion
To conclude, the phenotype of macrophages activated by polypropylene, polyethylene 
terephthalate and polylactic acid can be modulated using commonly used medications. 
Modulation of macrophages activated by other biomaterials than used in the current 
study, may be possible as well. The degree of the modulatory capacity however depends 
on the type of biomaterial that causes initial activation. Combined, this knowledge may 
provide insights into the possibility of using a medication in combination with a certain 
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biomaterial to direct macrophage behavior and thereby possibly avoiding unwanted 
effects after implantation of a biomaterial.
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supplementary figure s7.1: (a) The number of adhering macrophages on polypropylene, 
polyethylene terephthalate and polylactic acid after seeding followed by 6d of culture without 
modulation. (b) Protein secretion of macrophages without modulation in response to the 
biomaterials. Data shown as dot plots including the grand means for n=3 experiments per 
material. Statistical evaluation was conducted with one-way ANOVA tests after log-transformation 
followed by Bonferroni’s post hoc tests. Abbreviations: PP: polypropylene; PET: polyethylene 
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supplementary figure s7.2: Gene expression levels and protein levels of macrophages adhering 
to (a) polypropylene, (b) polyethylene terephthalate, and (C) polylactic acid. Two concentrations 
of medications were used in the experiments to modulate the biomaterial-adhering macrophages, 
yet showing minimal differences between concentrations. Statistical evaluation was conducted 
with a linear mixed model transformation followed by a Bonferroni’s post hoc test. P-values 
are only given for statistically significant differences between concentrations of the medications. 
Abbreviations: Rapa: rapamycin; Dex: dexamethasone; Cel: celecoxib; Prava: pravastatin. 
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supplementary figure s7.2 (continued): Gene expression levels and protein levels of macrophages 
adhering to (a) polypropylene, (b) polyethylene terephthalate, and (C) polylactic acid. Two 
concentrations of medications were used in the experiments to modulate the biomaterial-adhering 
macrophages, yet showing minimal differences between concentrations. Statistical evaluation 
was conducted with a linear mixed model transformation followed by a Bonferroni’s post hoc 
test. P-values are only given for statistically significant differences between concentrations of 
the medications. Abbreviations: Rapa: rapamycin; Dex: dexamethasone; Cel: celecoxib; Prava: 
pravastatin. 
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supplementary figure s7.2 (continued): Gene expression levels and protein levels of macrophages 
adhering to (a) polypropylene, (b) polyethylene terephthalate, and (C) polylactic acid. Two 
concentrations of medications were used in the experiments to modulate the biomaterial-adhering 
macrophages, yet showing minimal differences between concentrations. Statistical evaluation 
was conducted with a linear mixed model transformation followed by a Bonferroni’s post hoc 
test. P-values are only given for statistically significant differences between concentrations of 
the medications. Abbreviations: Rapa: rapamycin; Dex: dexamethasone; Cel: celecoxib; Prava: 
pravastatin.
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Osteoarthritis (OA) affects a large proportion of the population worldwide and its 
prevalence is expected to increase due to aging and obesity224. For several years now, 
the disease is considered as an inflammatory, degenerative disease affecting the whole 
joint and its surrounding tissues, rather than only the erosion of the articular cartilage 
that lines the bones. Synovial joints are enclosed by a synovial membrane, also known 
as the synovium, which secretes and holds synovial fluid within the joint cavity. Current 
treatments for OA are mainly focused on pain management, for instance physical 
therapy, systemic medications, or intra-articular injections. Unfortunately, there is no 
definite cure available that can conserve the entire joint. Therefore, new treatment 
strategies to delay the progression of OA are desired. One of the approaches is focusing 
on inflammation of the synovial membrane, a process in which macrophages are 
pivotal. Macrophages are derived from monocytes and are present in virtually all 
tissues of the body, including the synovium. They are key during innate and adaptive 
immunity and essential in joint homeostasis and inflammation4. Macrophages are 
unique in terms of their plasticity as they can become activated upon stimuli from 
their microenvironment. This process is usually referred to as polarization and results 
in a spectrum of phenotypes, ranging from pro-inflammatory macrophages (M1), to 
anti-inflammatory macrophages or tissue repair macrophages (M2). Because their 
homeostatic function can become compromised, macrophages are linked to numerous 
pathologies, including degenerative joint diseases. The aim of this thesis was to explore 
the involvement of macrophages, in particular the role of their phenotypes, during the 
processes of joint degeneration.
invoLveMent of MaCroPhage PhenotyPes in infLaMMatory 
tissUe Degeneration anD Degenerative Joint Disease.
Synovial inflammation is a major feature of OA, involving increased numbers of 
macrophages in the synovial tissue2-4,6. Early indications that macrophages in general 
can affect cartilage in vitro were reported in the ’70 and ‘80s48,49, where it was seen that 
macrophages were able to degrade cartilage explants. In the late ‘90s, other studies 
supported these early findings by use of an in vivo arthritis model where depletion 
of phagocytic synovial lining cells resulted in less influx of polymorphonuclear 
neutrophils. The depletion also resulted in reduced proteoglycan degradation and 
reduced chondrocyte death in cartilage after induction of collagen induced arthritis 
(CIA)127,225. It was further suggested that monocytes/macrophages were mainly 
responsible for this cartilage damage128. Later on, Blom et al. reported reduced formation 
of osteophytes, fibrosis, influx of inflammatory cells51, and MMP-mediated cartilage 
degradation52 when synovial macrophages were depleted from the synovial lining in 
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the collagenase-induced OA (CIOA) mouse model. These findings combined indicated 
that synovial macrophages are important regulators of joint tissue degeneration and OA 
development. Another study reported higher expression of CD11c, TNFA, MMP3, and 
a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) in the 
synovium of STR/Ort mice72, a model for spontaneous OA226,227, than in the synovium 
of C57BL/6 wildtype mice. The expression levels of these genes appeared to be linked 
to the pro-inflammatory F4/80+/CD11c+ macrophage population, which was increased 
in STR/Ort mice compared to the C57BL/6. Moreover, the levels were significantly 
reduced when the macrophages were depleted from the synovium, suggesting that 
F4/80+/CD11c+ macrophages are likely regulators of TNFA and MMP3 expression, 
factors that contribute to joint tissue degeneration.
Studies that focus on macrophages in joint diseases, mainly focus on an undefined 
macrophage populations or pro-inflammatory macrophages, even though the 
phenotype that a macrophage may acquire should be considered a spectrum, of which 
pro-inflammatory (M1) and anti-inflammatory (M2) are the extremes. M2 macrophages 
are both anti-inflammatory and involved in tissue repair. To distinguish these populations 
in vitro, M2-like macrophages are often further divided into IL-4 and/or IL-13 stimulated 
macrophages (M(IL4)) and IL-10 stimulated macrophages (M(IL-10)). These subsets 
are sometimes also referred to in literature as M2a and M2c macrophages39,59. As 
shown in chapter 5 and in agreement with work by others, different M2 macrophage 
populations can be generated by using certain stimuli in vitro42,43,68,73,118. M(IL4) 
macrophages where shown to highly express CD206 together with high expression 
and protein production of factors involved in tissue repair processes such as TGFβ, 
arginases, and CCL18111,112,117,118. M(IL-10) macrophages express high levels of CD163 
and produce high levels of IL-10 and soluble CD163, and are typically considered anti-
inflammatory45. These phenotypes are mainly used to characterize in vitro polarized 
macrophages. The knowledge on the effects of macrophages on joint tissues needed 
to be further expanded by distinguishing between these phenotypes. In chapter 3, the 
effects of the secreted products of three macrophage phenotypes on articular cartilage 
were evaluated in vitro. Therefore, conditioned media of M(IFNγ+TNFα), M(IL4), and 
M(IL10) polarized macrophages were prepared and cultured with cartilage explants of 
knee OA patients. Based on changes in gene expression levels, release of nitric oxide 
(NO) as an indication of inflammation, and release of glycosaminoglycans (GAGs) 
as an indication of cartilage degradation, it was shown that the secreted products of 
M(IFNγ+TNFα), enhanced inflammation and degeneration of the cartilage. Expression 
of catabolic genes and genes encoding for inflammatory proteins were upregulated, 
while the expression of genes encoding for matrix proteins were suppressed. In 
addition, products secreted by both M(IL4) and M(IL10) macrophages did not 
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prevent inflammatory processes in the cartilage and were also unable to inhibit acute 
inflammation or degeneration of the cartilage.
As in many other pathologies, OA progresses in stages. On a microscopic level, 
the synovial membrane of early OA patients contains more CD68+ macrophage 
infiltration than the synovium of late OA patients228. Immunohistochemical stainings 
of synovial tissue of end-stage hip OA patients (chapter 2) revealed that the majority of 
the macrophages in the synovium had an anti-inflammatory or tissue-repair phenotype. 
This was indicated by apparent staining of CD163+ and CD206+ cells, markers for 
anti-inflammatory and tissue repair macrophages, as well as increased gene expression 
levels identifying M(IL4+IL13) and M(IL10) macrophages. CD11c staining, a marker for 
pro-inflammatory macrophages, was almost completely absent. This was supported by 
low gene expression levels of TNFA and IL1B, markers indicative for pro-inflammatory 
macrophages. From these results we could speculate that the recruitment of additional 
monocytes into the synovial membrane by chemokines appears to result into the 
polarization of anti-inflammatory or tissue repair macrophage phenotypes. Together, 
the findings provide insights into the potential dynamics between chemokines, the 
phenotype of synovial macrophages, and the degenerative state of cartilage in end-
stage hip OA.
In terms of knee OA, it was found that patients with bicompartmental knee OA have 
a higher inflammatory profile than synovial fluid of patients with unicompartmental 
knee OA based on multiplex analysis and the CD14+ macrophages were the major 
cell population in both patient groups. The authors hypothesized that macrophages are 
relevant in the initiation stage of OA, and the stage of the disease may be predicted by 
the inflammatory profile of the synovial fluid229. Because soluble cytokines are good 
candidates to function as biomarkers, correlations between the presence of cytokines 
in the synovial fluid and OA stage have been explored extensively. The factors CCL2/
MCP-1 and IL-6 are known to be produced by macrophages68,230. The concentrations of 
both CCL2 and IL-6 in synovial fluid of patients undergoing knee arthroscopy, strongly 
correlated with the International Cartilage Repair Society (ICRS) cartilage score231. More 
direct evidence of the involvement of macrophages in OA was demonstrated by the 
correlation between concentrations of soluble CD14 (sCD14) and sCD163 in synovial 
fluid and the presence of activated macrophages in the joint capsule, and osteophyte 
severity and progression. Additionally, sCD14 concentrations in the synovial fluid was 
correlated with joint space narrowing severity86. CD14 is a surface receptor that is 
present on all monocytes and macrophages232,233, whereas CD163 is thought to be 
mainly present on anti-inflammatory macrophages42,68,234.
The presence of these markers in the synovial fluid, indicate a dynamic presence of 
different macrophage phenotypes during certain stages of OA. Managing the behavior 
of synovial macrophages may thus be a suitable approach to prevent the degeneration 
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of joint tissues. However, in order to utilize macrophage phenotype modulation as a 
therapeutic approach for OA, it should be first known which phenotypes are present 
during the course of the disease. Because the progression rate of OA varies among 
patients, experimental mouse models are useful. The time profiles of the presence 
of three macrophage phenotypes, which represent the extremes of the phenotype 
spectrum, were evaluated during the course of two experimental mouse models for 
OA (collagenase-induced OA and destabilization of the medial meniscus). These 
two models differ in degree of inflammation and degeneration rate. The OA knees 
were histologically evaluated 1, 3, 7, 14, 28, and 56 days after OA induction. iNOS 
was used as an immunohistochemical marker for pro-inflammatory macrophages, 
CD163 for anti-inflammatory macrophages, and CD206 as a marker for tissue-repair 
macrophages. The presence of the three macrophage phenotypes differed during OA 
onset and development. Moreover, the macrophage phenotypes were also differentially 
associated with the development and progression of OA characteristics such as synovial 
thickness, presence of osteophytes, and cartilage damage, which suggests that the 
different phenotypes of macrophages may have a different function in vivo as well.
MoDULation of MaCroPhage PhenotyPes to ControL 
infLaMMation
An approach to manage inflammation in synovial tissue as a treatment regimen for 
degenerative joint diseases, may be achieved by specific modulation of a macrophage 
population. Chemokines at the local site of inflammation may regulate recruitment 
and migration of monocytes, the precursors of macrophages. In light of this concept, in 
chapter 2, expression levels of chemokines that are related to monocyte extravasation, 
were measured in synovial tissue of end-stage hip OA patients. CCL2, CCL3, CCL4, 
CCL5, and CX3CL1 were all expressed in the synovium. CCL2 expression levels in the 
synovium had an inverse correlation with the cartilage degeneration of these patients 
as evaluated by histological analysis. Based on these findings, it could be speculated 
that CCL2 is involved in the recruitment of monocytes towards synovial tissue and once 
migrated, the monocytes appear to polarize towards an anti-inflammatory phenotype 
in end-stage hip OA. A next step would be investigating the actual involvement of CCL2 
on monocyte migration. Sophisticated in vitro systems such as microfluidic systems 
can be deployed to study cell extravasation235,236. Such information can benefit the 
development of strategies that influence trans-endothelial monocyte migration into 
joints, thereby directing synovial inflammation.
The knowledge on the profiles of the presence of these macrophage phenotypes 
during the course of OA (chapter 4), can be implemented to determine an optimal 
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timing to apply a treatment regimen that is focusing on modulation of macrophage 
phenotypes with the goal to inhibit OA progression. Therefore, in chapter 5, the 
possibility to modulate the macrophage phenotypes in synovial tissue in situ was 
assessed. To this aim, the modulatory capacity of medications or compounds that are 
commonly used in clinics was evaluated. The medications: dexamethasone, rapamycin, 
BMP-7, and pravastatin were chosen for this study and it was explored how this concept 
may be used to guide synovial inflammation. Each medication was able to guide the 
inflammatory state of the OA synovium via the modulation of specific macrophage 
phenotypes. More specifically, rapamycin enhanced acute inflammation of the synovial 
tissue, likely by specifically suppressing anti-inflammatory macrophages. On the other 
hand, dexamethasone reduced inflammation of the synovial explants which was 
likely regulated by suppression of pro-inflammatory macrophages with simultaneous 
enhancement of the performance of anti-inflammatory macrophages. Eventually, 
modulation of the inflammatory state of the synovium, can lead to an improved joint 
environment that may result into inhibition of cartilage degradation. This hypothesis 
was investigated by culturing OA cartilage explants with the conditioned medium of 
synovium that was modulated with the corticosteroid triamcinolone acetonide (TA) and 
with rapamycin (appendix chapter 5). The modulation of the synovium with rapamycin 
did not affect the degenerative state of the cartilage. Modulation of the synovium with 
TA however, resulted in reduced expression of the collagenases MMP1 and MMP13 in 
the cartilage, while expression of ACAN was enhanced. Also, hypertrophic processes 
appeared to be suppressed as indicated by lower expression of the hypertrophic cartilage 
marker COL10A1. Moreover, the capacity of the compounds to modulate macrophage 
phenotypes within the synovium, depended on the degree of inflammation in the 
tissue. These findings emphasize the importance of determining the inflammatory state 
of the synovium prior to any treatment that is focusing on macrophage modulation.
Several animal studies demonstrated that corticosteroids have to some extend the 
capacity to protect OA development by suppressing inflammation. In these studies 
however, the intervention is usually immediately applied after induction of OA144,147,237. 
In fact, in patient studies, conflicting effects on intra-articular corticosteroid injections 
are reported. These contradictions may likely be due to intervention timing and 
limitations in drug delivery. Non-post traumatic OA patients are seen in late stages of 
the disease by their health care provider. For instance, it has been reported that intra-
articular injections of triamcinolone every 3 months over a period of 2 years, actually 
increased cartilage loss and did not provide beneficial effects on pain for patients with 
Kellgren and Lawrence (KL) scores of 2 to 3 and the Western Ontario and McMaster 
Universities osteoarthritis index (WOMAC) scores of ≥2 and ≤8)238. Additionally, 
prolonged exposure to high concentrations of corticosteroids have actually been proven 
to be toxic for chondrocytes17,239. The possibility to modulate synovial inflammation 
Chapter 8
152
was challenged by simulation of acute inflammation in the synovial explants and the 
modulatory capacity of the medications varied based on the inflammatory state of the 
synovium (chapter 5). The profiles of macrophage phenotypes in time after OA onset, 
implicate that the susceptibility to modulate may be due to the different macrophage 
phenotypes present during a certain stage of the disease. As it was found in chapter 4 
that pro-inflammatory macrophages and tissue repair macrophages are mainly present 
during mid\late OA, whereas anti-inflammatory macrophages appear to be more 
pronounced during early OA in the mouse models, it is suggested that timing appears 
to be an important aspect when it comes to treatment of diseases with an inflammatory 
component in which macrophages have shown to be pivotal. To overcome delivery 
limitations, methods to encapsulate drugs (e.g., in lipid microspheres) with the goal 
to extend the retention of the drug, are of high interests. FX006/Zilretta (Flexion 
Therapeutics), is a novel formulation of TA enclosed in polylactic-co-glycolic acid 
(PLGA) microspheres that can remain for a prolonged period in the synovial fluid 
after intra-articular injection. FX006 showed promising results during Phase 2b240 
and Phase 3241 clinical trials. Compared to injections with non-encapsulated TA 
and placebo, FX006 demonstrated to have beneficial effects on pain, function, and 
stiffness of knee OA patients240-242. Additionally, the formulation ensues less systemic 
exposure than when not encapsulated243. To increase the efficacy even more, methods 
to specifically target specific cells, for example targeting synovial macrophages, can 
lead to the need of low drug concentrations and avoiding toxic effects of the drug. 
Currently, corticosteroid amounts in the order of magnitude of milligrams are injected 
intra-articularily240,244. From the work described in chapter 5, we know that with lower 
concentrations, 200 to 2000 times lower depending on the type of corticosteroid, it is 
already possible to modulate specific macrophage phenotypes. These findings indicate 
that inhibiting OA symptoms and progression via the modulation of the phenotype of 
synovial macrophages, may be efficient by improving delivery systems to direct the 
drug towards a specific macrophage phenotype.
Biomaterials are frequently used for joint reconstructions as well as in other fields of 
regenerative medicine. For instance, scaffolds constructed from copolymer composites 
can be used for cartilage tissue engineering245-248 with the ultimate goal to regenerate 
cartilage defects. To prevent further OA development due to meniscal injury or anterior 
crucial ligament injnury7, repair of the damaged tissue can be achieved with fixation249 
using suture materials (e.g., monofilament polyprolylene). Upon implantation of any 
biomaterial, the host will interact with the material and may exert a foreign body 
response involving macrophages. In chapter 6, the polarization behavior of monocytes 
into macrophages was evaluated using an in vitro culture model. To this extend, 
biomaterials were chosen that represent a class of materials often used in various clinical 
applications or cartilage tissue engineering: polypropylene, polyethylene terephthalate, 
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and polylactic acid. Interestingly, the inflammatory response of the macrophages could 
be predicted by the presence of subsets of monocytes in the peripheral blood of the patient 
and was revealed to be directed by obesity, a major risk factor of OA250,251. Based on the 
findings of chapter 6, the capacity to modulate the phenotype of macrophages when 
activated by a biomaterial was investigated in chapter 7. The medications rapamycin, 
dexamethasone, celecoxib, and pravastatin were all capable to modulate the phenotype 
of the macrophages that were activated by polypropylene, polyethylene terephthalate, 
or polylactic acid, though the modulatory capacity and susceptibility depended on the 
type of material. Improving the environment to allow joint tissue regeneration with the 
aid of biomaterials, may be accomplished by macrophage phenotype modulation. For 
such an approach, inspiration can be taken from the normal wound healing cascade 
which involves an inflammatory phase, proliferation phase, and tissue remodeling 
phase252. Thus, stimulating inflammation in a controlled way, followed by controlled 
tissue repair processes may benefit tissue regeneration. It was reported that cartilage 
engineered constructs may support polarization of activated macrophages into an 
anti-inflammatory state, resulting in favorable cartilage generation253. Another study 
showed that producing a scaffold that is capable of sequentially releasing cytokines 
known to modulate macrophage phenotypes to mimic the phases of wound healing, 
improves bone tissue engineering254. The combination of such a tool and the findings of 
chapters 6 and 7, may provide insights for applying macrophage phenotype modulation 
for improving biomaterial-based joint tissue regeneration strategies.
fUtUre PersPeCtives
functional role of macrophage phenotypes and their potential role in oa 
development
Besides modulation of macrophage phenotypes with the aim to suppress OA 
development, modulating the angiogenesis-stimulating behavior of macrophages 
would also be interesting. An important characteristic of OA, though less addressed in 
this thesis, is the alteration of the osteochondral junction, the transitional area in which 
cartilage meets bone. These are accompanied by the vascular invasion of the calcified 
cartilage, followed by the penetration of the calcified cartilage into the articular 
cartilage255,256. These events can lead to cartilage calcification and, most likely, to pain 
and loss of function. One study reported that vascularization of articular cartilage and 
synovial angiogenesis is present in early OA and is associated with cartilage damage, 
osteophyte formation, and synovitis256. Macrophages are also known to be involved in 
angiogenesis and vascularization, though insights in the mode of action and mechanisms 
during OA onset and progression are limited. Reports are somewhat contradictive, as 
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these cells tend to regulate vessel network growth both directly and indirectly257. One 
study reported that M(IL-4) and M(IL-10) M2 macrophages derived from murine bone 
marrow, promote angiogenesis in vitro and in vivo when encapsulated in Matrigel 
after subcutaneous implantation258. On the other hand, an in vitro study revealed 
that pro-inflammatory (M1) human monocyte-derived macrophages are initiators of 
angiogenesis and vascularization in 3D Matrigel scaffolds257. This initiation is directed 
by the macrophages via secretion of pro-angiogenic factors, such as VEGFA, FGF, and 
MMP9. The presence of macrophages in the synovial membrane during the course of 
OA was associated with the presence of osteophytes, while in the control knees no 
associations were found (chapter 4). These data combined suggest that macrophages 
may have a role in promoting bone formation and that this capacity may depend on the 
ability of macrophages to regulate angiogenesis and vascularization. A next step could 
be investigating the functional effects of different macrophage phenotypes during OA 
in vivo. For instance, by developing an animal model in which only one phenotype 
is present. This may be achieved by first depleting the macrophages, followed by 
reconstitution with a single phenotype of macrophages that has been generated in 
vitro259. After this model has been validated for this purpose, it can then be used to 
investigate the functional role of phenotypes in the pathogenesis of OA, and potentially 
elucidate further mechanisms such as calcification of articular cartilage and the 
identification of mechanisms promoting angiogenesis and vascularization in the joint. 
These findings can subsequently contribute to the identification of new potential drug 
targets to inhibit the invasion of subchondral bone into articular cartilage.
In vivo imaging of macrophage phenotypes in oa
Ideally, a minimally invasive tool to either predict OA progression or to assess the stage 
of the disease would be desirable, so that a macrophage modulation-based therapy can 
be applied efficiently. One study reported an association between synovial inflammation 
detected by ultrasound and the development of bone erosions in hand OA260. Though 
informative, methods to specifically image macrophages would be preferable. As the 
presence of synovial macrophages or their products are correlated with OA progression, 
in vivo imaging of activated macrophages has become of interest. The folate receptor 
β (FR-β) has become an interesting target ligand for activated macrophages. It was 
shown that injection of a folic acid analog labeled with a radio nucleotide followed 
by single-photon emission computed tomography (SPECT) combined with computed 
tomography (CT) could be used as an imaging tool to assess macrophage activation in 
experimental OA in rats261. One study reported a method to image of FR-β+ activated 
macrophages with a receptor specific imaging agent (99mTc-EC20/Etarfolatide) using 
SPECT/CT imaging of radiographic OA knees. The association found between the 
number of activated macrophages, and radiographic knee OA severity also suggested 
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that drug delivery by specifically targeting activated macrophages via FR-β could be a 
possibility262, though targeting specific macrophage phenotypes would be even more 
preferable (chapter 5). However, imaging of these macrophages to actually distinguish 
a macrophage phenotype remains challenging. For instance, reports regarding FR-β 
as a marker for a macrophage phenotype are somewhat controversial, as studies 
have reported that FR-β+ macrophages can be seen as a marker for pro-inflammatory 
macrophages263,264, or anti- inflammatory macrophages147, as the expression of the 
receptor seems to be coupled with the expression of both M1 and M2 markers164, 
which makes distinction in vivo between the phenotypes challenging. In another recent 
study265, a tracer (cFLFLF-PEG-64Cu) was developed consisting of a probe that targets 
formyl peptide receptor-1 (Fpr1), and was used to visualize macrophages via positron 
emission tomography (PET) in the monosodium iodoacetate (MIA) model of OA in 
rats. Stronger signal of the tracer was found in the MIA injected knees than in the 
controls, and the probe had mainly accumulated in the synovial membrane of the MIA 
knees. Additionally, high binding of the probe was found in RAW264.7-derived M(LPS) 
suggesting specific binding to pro-inflammatory macrophages, and indicating that the 
probe could be used to specifically visualize and target Fpr1 expressing macrophages 
in an OA joint. These studies demonstrate that specific imaging of macrophages is 
a relative new, yet interesting field. When fully exploited, for instance imaging of a 
specific phenotype so visualize the balance between subsets within tissue, could 
considerably contribute to current OA treatment regimens.
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The first research question that contributes to the main aim of the thesis was: How 
are macrophages of different phenotypes involved in inflammatory tissue degeneration 
and degenerative joint diseases? This question was mainly addressed in chapters 2 to 
5 (Figure 9.1). In this thesis, a distinction between three main phenotypes was made: 
pro-inflammatory, anti-inflammatory, and tissue repair macrophages, of which their in 
vitro counterparts were defined as: M(IFNγ+TNFα), M(IL-10), and M(IL-4), respectively 
(chapters 2, 3, 5). Our first step towards answering the question was revealed in chapter 
3, where it was found that pro-inflammatory macrophages exacerbated cartilage 
degeneration by increasing production of NO, increasing release of GAGs, and 
stimulation of cartilage matrix degrading enzymes and inflammatory proteins (Figure 
9.1, bottom left). In our next step, we investigated which phenotypes of macrophages 
were mainly present in the synovial tissue of end-stage OA patients. It was seen that the 
tissue repair macrophages were the predominant phenotype present in the synovium of 
these patients (chapter 2). We could also speculate that chemokines, and in particular 
expression of CCL2, are involved in facilitating monocyte recruitment into synovium 
followed by polarization into anti-inflammatory and tissue repair macrophages (Figure 
9.1, upper right, dashed lines). Finally, to see the whole picture, we mapped the 
presence of three macrophage phenotypes during the course of OA in vivo (chapter 
4) and it was found that anti-inflammatory macrophages appear early after OA onset, 
while pro-inflammatory and tissue repair macrophages appear in mid to late stage OA 
(Figure 9.1, middle).
The second research question of this thesis was: How can modulation of macrophage 
phenotypes be applied to control either inflammation or their response to biomaterials? 
This question was mainly addressed in chapters 4 to 7. Chapter 5 revealed that common 
medications (corticosteroids, rapamycin, BMP-7, and pravastatin) were able to direct 
synovial inflammation in situ by effecting specific macrophage phenotypes (Figure 9.1, 
bottom). Modulation of the synovium by a corticosteroid also had a positive functional 
effect on cartilage explant degeneration by inhibiting matrix degrading proteins and 
inhibition of chondrocyte hypertrophy, likely due to enhancing the performance of 
tissue repair macrophages (appendix chapter 5). Moreover, chapter 4 revealed that 
the three macrophage phenotypes are also likely to have specific functions in vivo by 
suppressing osteophyte formation and synovial inflammation (Figure 9.1, bottom right). 
An inflamed tissue environment may impede biomaterial-based joint reconstruction 
and regeneration. It was found that monocytes are likely to polarize towards 
pro-inflammatory macrophages in response to biomaterials which was even aggravated 
by obesity (Figure 9.1, upper left). Finally, with the idea to be able to intervene these 
processes, we have shown as proof of concept that the behavior of the macrophages in 
response to a biomaterial can also be modulated by drugs (Figure 9.1, middle).
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ConCLUDing reMarks
To conclude, the work described in this thesis revealed that pro-infl ammatory, anti-
infl ammatory, and tissue repair macrophages each have their own behavior and 
association with OA development and progression. The studies in this thesis present 
methods on specifi cally modulating a macrophage phenotype within tissue with 
the ultimate goal: suppressing OA progression. These methods can be interpreted as 
guidelines for selecting the most suitable approach for modulation while taking into 
account the stage of the disease, the infl ammatory state of the tissue, or the type of 
biomaterial in case of biomaterial-based joint tissue regeneration. The knowledge can 
be applied to use macrophage phenotype modulation as a tool to intervene or suppress 
processes that contribute to degeneration of joint tissues.
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Een veel voorkomende gewrichtsaandoeningen is artrose. Wereldwijd lijdt een groot 
deel van de samenleving aan deze gewrichtsziekte en het aantal personen zal in de 
komende jaren toenemen, voornamelijk door de vergrijzing van de populatie en 
overgewicht. Tegenwoordig wordt de ziekte niet meer gezien als simpelweg slijtage 
van het kraakbeen, maar als een inflammatoire, degeneratieve ziekte die het gehele 
gewricht en bijbehorende weefsels aantast. Synoviale gewrichten worden omgeven door 
een synoviale membraan, ook wel synovium genoemd. Het membraan produceert de 
synoviale vloeistof wat als smeermiddel fungeert waardoor beweging van de botdelen 
weinig wrijvingsweerstand ondervindt.
De huidige therapie is voornamelijk gericht op behandeling van de pijn met behulp 
van systemische en soms ook intra articulaire medicatie vaak gecombineerd met 
oefentherapie. Wanneer pijnbestrijding niet voldoende is kan een gewrichtsprothese 
geplaatst worden. Om chirurgische behandeling te voorkomen zijn nieuwe therapieën 
gewenst die de progressie van artrose kunnen doen vertragen. Eén van de benaderingen 
is te concentreren op synoviale inflammatie, een proces waarin macrofagen cruciaal 
zijn. Macrofagen stammen af van monocyten en zijn aanwezig in alle weefsels van 
het lichaam, zo ook het synoviale membraan. Ze zijn van groot belang gedurende 
aangeboren- en verkregen immuunreacties en essentieel in gewrichtshomeostase en 
inflammatie. Macrofagen zijn uniek vanwege hun plastische eigenschap. Ze kunnen 
geactiveerd worden door stimuli uit de omgeving, een proces dat resulteert in een 
spectrum van fenotypen wat kan variëren van pro-inflammatoir (ontstekingsbevorderend) 
(M1) tot anti-inflammatoir en weefsel herstellend (M2). Aangezien de homeostatische 
functie van macrofagen kan worden aangetast, zijn macrofagen geassocieerd met diverse 
aandoeningen waaronder degeneratieve gewrichtsziekten. Het doel van dit proefschrift 
was: het bestuderen van om de betrokkenheid van macrofagen, in het bijzonder de rol 
van hun fenotype, gedurende processen betrokken bij gewricht degeneratie.
Synoviale inflammatie is een belangrijk kenmerk van artrose en gaat vaak gepaard 
met verhoogde aantallen van macrofagen in het synoviale weefsel. Chemokinen zijn 
betrokken bij de regulatie van het aantrekken van monocyten, de voorlopers van 
macrofagen. In het kader van dit concept werd er in hoofdstuk 2 in het synovium 
van heup artrose patiënten, gekeken naar genexpressie niveaus van chemokinen die 
gerelateerd zijn aan monocyt migratie. Van dezelfde patiënten werd ook gekeken 
naar de schade en degeneratieve staat van het articulaire kraakbeen van de femurkop. 
Er werd in tegenstelling tot de verwachting een omgekeerde correlatie gevonden 
tussen de expressie van CCL2 in het synovium en de degeneratieve staat van het 
kraakbeen. Aangezien dit een onverwachte bevinding was, hebben we gekeken welk 
macrofaag-fenotype het meeste frequent aanwezig was in het synovium. Met behulp 
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van een immunohistochemische kleuring vonden we voornamelijk CD206+ en CD163+ 
cellen in het synovium, een indicatie voor de aanwezigheid van weefselherstellende 
en anti-inflammatoire macrofagen. Daarnaast was de expressie verhoogd van genen 
die een indicatie geven voor M(IL4+IL13) en M(IL10) macrofagen. Gebaseerd op 
deze bevindingen, kunnen we concluderen dat CCL2 betrokken is in eindstadium 
heupatrose. We kunnen speculeren dat het aantrekken van additionele monocyten 
wellicht niet nadelig hoeft zijn, omdat de gemigreerde monocyten kunnen polariseren 
in anti-inflammatoire of weefselherstellende macrofagen.
In vitro experimenten uit de jaren ’70 en ’80 hebben laten zien dat macrofagen 
in het algemeen kraakbeen weefsel kunnen aantasten. Hierbij werd echter geen 
onderscheid gemaakt tussen de effecten van de verschillende fenotypen. In hoofdstuk 
3 wordt beschreven welke effecten de secretie producten van macrofagen van drie 
verschillende fenotypen hadden op artrotisch kraakbeen afkomstig uit het kniegewricht. 
Hiervoor werd geconditioneerd kweekmedium geproduceerd door M(IFNγ+TNFα), 
M(IL4) en M(IL10) gepolariseerde macrofagen waarin kraakbeen weefsel van artrose 
patiënten werd gekweekt. Op basis van genexpressie, productie van stikstofmonoxide 
(NO) en het vrijkomen van glycosaminoglycanen van het kraakbeen, concludeerden 
we dat M(IFNγ+TNFα) macrofagen de inflammatie en degeneratie versterkten. De 
expressie van katabole genen en genen die coderen voor inflammatoire eiwitten waren 
verhoogd, terwijl de expressie van genen die coderen voor matrix eiwitten, waren 
onderdrukt. Ook waren de producten van M(IL4) en M(IL10) macrofagen niet in staat 
om de inflammatoire- en degeneratieve processen in het kraakbeen te verlichten. 
Deze bevindingen geven aan dat het managen van het fenotypen van synoviale 
macrofagen gunstig kan zijn om verdere degeneratie van kraakbeen te voorkomen. 
Dit kan worden gedaan door pro-inflammatoire macrofagen te onderdrukken of de 
efficiëntie van anti-inflammatoire macrofagen te versterken. Om deze benadering 
efficiënt in te zetten, is het nodig dat we weten welke fenotype macrofaag aanwezig 
is in het synovium gedurende een bepaalde periode van de ziekte. Daarom werd 
er in hoofdstuk 4 gekeken naar de aanwezigheid van drie macrofaag fenotypen die 
de extremen van het spectrum van de fenotypen representeren. Omdat de mate van 
progressie van artrose varieert onder patiënten, werd er gebruik gemaakt van twee 
muismodellen voor artrose die verschilden in mate van inflammatie en gewichtsweefsel 
degeneratie. De aanwezigheid van de drie macrofaag fenotypen varieerden na artrose 
inductie en gedurende de verdere ontwikkeling van artrose. De fenotypen waren ook 
geassocieerd met kenmerken voor artrose, zoals de dikte van het synoviale membraan, 
de aanwezigheid van osteofyten en kraakbeen schade. De kennis over de profielen in 
de tijd van de verschillende fenotypen gedurende artrose, kan worden ingezet om een 
optimale tijd te bepalen voor het inzetten van een therapie die een specifiek fenotype 
kan moduleren met als doel de progressie van artrose te vertragen.
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Na het bepalen van de macrofaag fenotypen, werd geanalyseerd op welke manier 
we specifiek het fenotype van macrofagen kunnen moduleren om synoviale inflammatie 
te remmen. Dit werd in hoofdstuk 5 bestudeerd door de modulatoire capaciteit van een 
viertal veelgebruikte geneesmiddelen te onderzoeken. Synoviaal weefsel van knie artrose 
patiënten werd behandeld met dexamethason, rapamycine, BMP-7 of pravastatine. 
De inflammatoire toestand van het synovium kon worden gestuurd via modulatie van 
specifieke macrofaag fenotypen. Specifiek gezien, zorgde rapamycine voor een pro-
inflammatoir effect op het synovium wat hoogstwaarschijnlijk bewerkstelligd werd door 
specifieke onderdrukking van anti-inflammatoire macrofagen. Anderzijds onderdrukte 
dexamethason de inflammatie in het synovium, waarschijnlijk via onderdrukking van 
pro-inflammatoire macrofagen en tegelijkertijd versterken van de anti-inflammatoire 
macrofagen. De capaciteit van de medicatie om synoviale inflammatie te moduleren 
ging echter gepaard met de inflammatoire staat van het weefsel, hetgeen benadrukt dat 
het van belang is om deze toestand van tevoren te kunnen vaststellen.
Obesitas is een stijgend probleem in de Westerse samenleving en is een risico 
factor voor artrose. Het is ook een van de redenen dat het wordt verwacht dat de 
prevalentie van OA zal stijgen in de komende jaren. Biomaterialen worden veel 
gebruikt in diverse (onderzoeks)gebieden van de (regeneratieve) geneeskunde. Na 
implantatie zal het lichaam op het materiaal reageren een lichaamsvreemd reactie 
initiëren. Tijdens deze reactie spelen macrofagen een grote rol. In hoofdstuk 6 werd 
het gedrag van monocyten van obese patiënten onderzocht nadat deze werden 
geactiveerd in reactie op een biomateriaal. Hiervoor werden biomaterialen gekozen 
die een groep vertegenwoordigen van frequent gebruikte biomaterialen voor diverse 
klinische toepassingen: polypropyleen, polyethyleentereftalaat en polymelkzuur. 
Hierbij werd gezien dan obesitas het gedrag van de macrofagen beïnvloedt richting een 
overwegend pro-inflammatoir fenotype. Daarnaast kon dit gedrag worden voorspeld 
door te kijken naar subsets van monocyten in het bloed van de patiënt. Gebaseerd op 
deze bevindingen, hebben we in hoofdstuk 7 onderzocht of dit gedrag kon worden 
gemoduleerd. De medicijnen rapamycine, dexamethason, celecoxib en pravastatine 
hadden allen de capaciteit om het fenotype van de macrofagen die werden geactiveerd 
door polypropyleen, polyethyleentereftalaat en polymelkzuur, te beïnvloeden. 
Daarnaast werd gezien dat de gevoeligheid voor modulatie afhankelijk was van het 
type materiaal.
Concluderend, het onderzoek beschreven in dit proefschrift heeft laten zien dat 
pro-inflammatoire, anti-inflammatoire- en weefselherstellende macrofagen ieder een 
eigen gedrag hebben en een associatie hebben met artrose ontwikkeling en progressie. 
De onderzoeken bij elkaar presenteren methodes om specifiek macrofaag fenotypen 
in weefsel te moduleren, met als einddoel de progressie van artrose vertragen. Deze 
methoden kunnen worden geïnterpreteerd als richtlijnen voor het selecteren van 
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de meest geschikte modulatie methode in acht nemend het stadium van de ziekte, 
de mate van inflammatie in het weefsel, of het type biomateriaal in het geval van 
gewrichtsregeneratie met behulp van biomaterialen. De kennis beschreven in dit 
proefschrift kan worden toegepast als een hulpmiddel om processen te onderdrukken 
die bijdragen aan degeneratie van gewrichtsweefsels.
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List of abbreviations
ACAN aggrecan
ADAMTS A Disintegrin And Metalloproteinase with Thrombospondin Motifs
ALPL alkaline phosphatase
BMP bone morphogenetic protein
CCL C-C motif ligand
CCR C-C chemokine receptor
CD cluster of differentiation
CIA collagen-induced arthritis
CIOA collagenase-induced osteoarthritis
Cel Celecoxib
COL10A1 collagen type X
COL2A1 collagen type II
COMP cartilage oligomeric matrix protein
CRP C-reactive protein
CXCL chemokine (C-X-C motif) ligand
Dex dexamethasone
DMM destabilization of the medial meniscus
DMOADs disease-modifying osteoarthriits drugs
DMSO dimethyl sulfoxide
FBS fetal bovine serum
FR folate receptor
GAG glycosaminoglycan
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GM-CSF granulocyte-macrophage colony-stimulating factor
IFN interferon
IHH indian hedgehog
IL interleukin
iNOS inducible nitric oxide synthase
LPS lipopolysaccharide
MACS magnetic-activated cell sorting
MCM macrophage conditioned medium
MCP-1/CCL2 monocyte chemoattractant protein-1
M-CSF macrophage colony-stimulating factor
MIP-1α/CCL3 macrophage inflammatory protein alpha
MIP-1β/CCL4 macrophage inflammatory protein beta
MMP matrix-metalloproteinase
MMTL medial meniscotibial ligament
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mPET polyethylene terephthalate (multifilament)
MSC mesenchymal stem cell
mTOR mechanistic/mammalian target of rapamycin
NO nitric oxide
NSAIDs non-steroidal anti-inflammatory drugs
OA osteoarthritis
PBMC peripheral blood mononuclear cell
PET polyethylene terephthalate (monofilament)
PLA polylactic acid
PP polypropylene
Prava pravastatin
RANTES/CCL5 regulated on activation, normal T cell expressed and secreted
Rapa rapamycin
RUNX Runt-related transcription factor
SCM synovium conditioned medium
SOCS suppressor of cytokine signaling
TA triamcinolone acetonide
TGF transforming growth factor
TNF tumor necrosis factor
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